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Summary 
Airway branching and vascular growth in the developing lung are intimately co-
ordinated processes which involve cross-talk between the primary inducer of airway 
tube elongation, Fibroblast Growth Factor 10 (FGF10) and the pro-vasculogenic 
transcription factor, Hypoxia Inducible Factor 1α (HIF-1α).  The FGF receptor 
antagonist, Sprouty2 (SPRY2), influences the duration of this signalling activity and 
thus governs periodical airway and vascular branching.  However, the mechanism 
behind this coordination is unknown.  The aim of this thesis was to establish if SPRY2 
acts as a key co-ordinator of airway and vascular development in the fetal lung and 
to explore the implications of this role for vasculogenic signalling from the 
endodermal epithelium. 
 
SPRY2 is present in the nucleus in both rat Fetal Distal Lung Epithelial (FDLE) and 
Human Bronchial Epithelial (HBE) cells where its FGF10-induced loss correlates with 
an increase in Histone 3 (H3) phospho-acetylation.  Chromatin Immunoprecipitation 
(ChIP) assays revealed a dominant interaction between SPRY2 and GC-rich regions of 
the Vascular Endothelial Growth Factor (VEGF-A) promoter.  Mutation of SPRY2 at 
tyrosine 55 (Y55) and SH3 motifs induced HIF-1α transcriptional activity while by 
contrast; cysteine mutation suppressed this activity and abolished SPRY2 interaction 
with the VEGF-A promoter.  Knockdown of SPRY2 by shRNA induced phosphorylation 
of Extracellular Signal-regulated Kinases 1 & 2 (ERK1/2) and Mammalian Target of 
Rapamycin Complex 1 (mTORC1) while also amplifying VEGF-A gene expression.  
Knockdown of SPRY2 amplified HIF-1α transcriptional activity approximately 3.5 fold 
at normoxia and this was reflected in ChIP assays showing increased association of 
HIF-1α with the VEGF-A promoter.  
 
Taken as a whole, this data supports the hypothesis that SPRY2 is potentially the 
‘missing link’ responsible for co-ordinated airway and vascular growth of the lung 
epithelium.  It achieves this by regulating vascular gene expression by binding to 
methylation sites of the VEGF-A promoter, coupled with the potential for SPRY2 to 
bind G-proteins to its SH3 binding domain in order to silence airway and potentially 
vascular signalling cues from the epithelium. 
1 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 - General Introduction 
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The mammalian lung 
 
Every living organism requires energy to survive and this energy is principally derived 
from food intake and the inhalation of oxygen required for respiration and metabolic 
processes.  For air-breathing animals, the lung is the essential respiring organ which 
transports atmospheric oxygen into the bloodstream in concurrence with the 
expulsion of carbon dioxide produced by cells back into the atmosphere.  Inhaled air 
is breathed in through the nasal or oral passage and passes down into the trachea 
which branches into single left and right bronchi.  Each bronchus enters each lung 
lobe itself and further partitions into bronchioles which supply air into millions of 
tiny air sacs called the alveoli, a group of specialised cells surrounded by an extensive 
capillary network.  The vast number of alveoli in the lungs provides an ideal huge 
surface area for gas exchange to occur.  Gas exchange between the air and the blood 
occurs across the thin walls of the alveoli; the blood-air barrier. Oxygen diffuses 
through this barrier into the blood coupled with the transport of carbon dioxide 
produced by the cells back into the alveoli before exhalation.  The maintenance of 
this diffusion is kept in stasis by continuous breathing of fresh air into the lungs.  
However, this mechanism also requires energy through the means of muscular 
contraction of the external intercostal muscles and the diaphragm.  The unique 
structure of the lungs and the complexity of the mammalian respiratory system 
arises from a series of co-ordinated biochemical, biophysical and molecular events, 
which stem from early embryonic development (McMurty, 2002).  
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Development of the mammalian lung 
 
Lung development occurs under surprisingly extreme conditions.  In utero, the lung 
grows at hypoxia, a partial pressure (pO2) akin to the summit of Mount Everest (3% 
O2, ~23mmHg).  Development must be sustained to allow gas exchange to 
incorporate normoxic conditions upon birth (21% O2, ~100mmHg).  Adult human 
beings only experience hypoxia through scaling high altitudes, but there are several 
instances where the lung has experienced localised or global hypoxia physiologically 
or pathologically (Shimoda & Semenza, 2011).   
 
Figure 1.1. The stages of lung development.  See text for details (diagram adapted 
from Resp!Rare, 2012). 
Development of the human embryonic lung (Figure 1.1) commences around 3-7 
weeks of gestation with the emergence of a primitive lung bud (Figure 1.1A), the 
laryngo-tracheal groove, which is derived from the foregut endoderm (Del Moral et 
al., 2006).  This groove rapidly induces the formation of the trachea and another 
4 
 
 
 
primitive lung bud, which then elongates and divides into two main bronchi 
(Mailleux et al., 2001).  Around the age of 4.5 weeks, five tiny saccules are visible; 
two on the left-hand side and three on the right, which will ultimately form the lobar 
bronchi and corresponding lung lobes.  These primitive lung buds are also lined with 
epithelium derived from differentiated endodermal cells, which coat the conducting 
respiratory airways (Ten Have-Opbroek, 1991).  Smooth muscle and early blood 
vessel formation also occurs, which is induced by mesenchymal cells surrounding the 
developing airway (Deutsch & Pinar, 2002).   
 
The pseudoglandular phase (7-16 weeks; Figure 1.1B) is a critical stage in the 
formation of the airway.  This is where branching morphogenesis occurs, in which 
the acinar tubules are formed from rapid dichotomous branching of the lung’s 
peripheral bud network (Finney et al., 2008).  This dichotomous growth is of a fractal 
nature and continues to branch into the mesenchyme of the visceral pleura (Weibel, 
2009) for approximately 10 weeks.  This phase is also defined by the appearance of 
differentiated columnar epithelial cells, which line the bronchiole tubules.  The 
airways and major blood vessels also become coated with smooth muscle (Bucher & 
Reid, 1961) and a series of pulmonary vessels sprout from the pulmonary artery to 
line the branching epithelium and extend into the surrounding mesenchyme.   
Epithelial morphogenesis of the airway branch network is sustained by an 
intraluminal pressure, which is also linked in determining the rate of vascular 
development of the lung (Unbekandt et al., 2008). 
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The canalicular phase (16-26 weeks; Figure 1.1C) is characterised by intense vascular 
development (highlighted by the red outline of the airways in Figure 1.1C) and the 
differentiation of the epithelium surrounding the alveolar ducts.  In this phase, the 
alveolar type I and II pneumocytes (ATI, ATII) are first observed, formed from 
differentiation of the cuboidal epithelial cells (Deutsch & Pinar, 2002).  The growth of 
major blood vessels and differentiation of the pulmonary epithelium also occurs 
leading to the formation of the air-blood barrier, providing the capability for gas 
exchange (Burri & Moschopulos, 1992).  Several studies have shown that throughout 
mid-gestation, the airway epithelium is in close proximation with the endothelium, 
whose cells comprise the air-blood barrier (Hislop, 2002). 
 
In the saccular phase (28-35 weeks; Figure 1.1D), the epithelium continues to 
differentiate giving rise to the alveolar epithelial cells, a group of specialised ATI and 
ATII cells.  In doing so they become the most populated group of epithelial cells in 
the fetal lung (Deutsch & Pinar, 2002), comprising 99% of the lung’s surface area.   
Smooth-walled sacculi appear at the terminus of each respiratory tract forming a 
matrix with the neighbouring septa, which permits further growth and 
differentiation of the epithelium (Rannels & Rannels, 1989).   
 
The final stage of lung development is the alveolar phase (36 weeks up through 
infancy; Figure 1.1E) where by this point approximately 23 generations of airway 
branching has occurred (Weibel, 2009), along with the formation of approximately 
150 million alveoli, which is between a third and a half of those found in the adult 
lung (Hislop et al., 1986).  This allows oxygen to be supplied upon birth while alveolar 
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development continues for at least 2-3 years after birth in humans and matures over 
the first seven years of life.  The pulmonary vasculature is radically transformed at 
birth upon first breath and postnatally continues to develop exponentially, closely 
matching the rate of alveolarisation (Gebb & Torday, 2008). 
The formation and role of the pulmonary epithelium in regulating 
normal lung function.    
 
Upon normal branching morphogenesis, a vast network of hollow tubes form, which 
are comprised of a variety of endothelial and epithelial cell types (Metzger & 
Krasnow, 1999).  A layer of pseudostratified epithelium coats the trachea and 
bronchi and the proximal airways themselves are composed of columnar epithelium.  
This is defined as the pulmonary epithelium, which is composed of a number of 
specialised epithelial cells that serve to maintain proper lung function by regulating 
lung fluid balance, gas exchange, ion transport and acting as barriers to foreign 
agents (Hermans & Bernard, 1999). 
Pulmonary Neuroendocrine Cells (PNEC) 
 
PNECs are one of the earliest epithelial phenotypes observed in lung development 
(~E13.5) (Shan et al., 2007) and their formation in the proximal airways is thought to 
be regulated by Notch signalling (Rock & Hogan, 2011).  Their function in fetal 
development is to supply prospective airways with a series of peptides to aid 
signalling of branching morphogenesis (Sunday, 1996).  Little is known of the long-
term function of PNEC’s but it is thought that they play a role in mediating epithelial 
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cell turnover via paracrine mechanisms, as well as a playing a chemosensory role in 
detecting hypoxia (Cutz, 1982). 
Ciliated cells 
 
Ciliated cells possess a columnar morphology and coat the tracheal and bronchial 
regions of the lung.  Their function is to secrete a mucosal layer which surrounds the 
pulmonary epithelium that serves as a barrier to infection.  In tandem with the 
goblet cells, the sweeping action of the cilia propels away any particulate matter 
adhered to the mucosal layer.  It is also suggested that ciliated cells play a role in 
restoring airway tissue damage (Lawson et al., 2002).   
Goblet cells 
 
Goblet cells are a group of specialised ciliated columnar epithelial cells which secrete 
mucous glycoproteins into the bronchial lumen allowing the surface fluid to trap 
particulate matter and thus protecting the epithelial membrane (Chang et al., 2008).  
However, in many lung-associated diseases, such as asthma, goblet cell proliferation 
(hyperplasia) results in a build-up of mucous secretion around airway ducts and thus 
can compromise airway function (Chang et al., 2008) 
Clara cells 
 
Clara cells are non-ciliated columnar cells which are localised in the conducting 
airways and bronchioles in large mammals (Chang et al., 2008).  Their main function 
is to express surfactant proteins which are responsible for reducing surface tension 
throughout the lung and thus prevent lung collapse.  An additional function of these 
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cells is to eradicate toxins dissolved in the airway lumen (Widdicombe, 2002).   Clara 
cells also have unique stem cell capabilities (Bishop, 2004) and have been reported 
to be involved in the regeneration of the lung structure (Rawlins et al., 2009).  As 
such, clara cells have long been regarded to act as progenitors of cells for the 
terminal bronchioles (Bishop, 2004). 
Alveolar Type I and II Pneumocytes 
 
The large, flat morphology of the ATI cells serve to provide a large surface area 
suitable for gas exchange (Williams, 2003).  By contrast, ATII cells are cuboidal in 
appearance and are responsible for the recruitment of surfactant molecules and 
proteins to their lamellar bodies in order to aid host defence from infections 
(Whitsett et al., 2010), as well assist fluid and ion transport across the airway 
epithelium (Kemp & Oliver, 1996).  In contrast to their ATII counterpart, relatively 
little is known regarding the function of ATI cells as they have proven to be difficult 
to isolate in vitro (Berthiaume et al., 2006).  One function for ATI cells postulated by 
Chen et al., (2006), suggests that they protect the alveolar epithelium from oxidative 
stress by secreting antioxidant proteins such as Apolipoprotein E (Apo E) and 
Transferrin.  Interestingly, ATI cells are unique in that they do not undergo mitotic 
division and depend upon mitosis and differentiation of their ATII counterpart (Evans 
et al., 1975).  
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Development of the pulmonary vasculature. 
 
The majority of studies on branching morphogenesis have focused specifically on the 
formation of the bronchial tree.  However, there is evidence to suggest that the 
airway tree formation is co-ordinated with development of the vascular tree via 
pulmonary circulation (Glenny, 2010).  The lung becomes vascularised as early as the 
pseudoglandular phase with the vascularisation of the primitive lung bud through 
the ingrowth of a vascular plexus form the heart/aortic sac and dorsal aorta (Jones & 
Capen, 2011).  This primitive aorta and pulmonary trunk gives rise to the circulatory 
mechanism that exists between the heart and the lung capillary plexus (Gao & Raj, 
2010).  At this point, a mesenchymal capillary plexus forms resulting in the 
emergence of pulmonary macrovascular (arteries and veins) and microvascular 
(capillaries) structures (Hall et al., 2002; deMello et al., 1997).  The mesenchyme is 
derived from the lateral plate mesoderm and introduces a raft of vascular progenitor 
cells, such as smooth muscle and endothelial cells (Hislop, 2005).  This forms a 
vascular network in the mesenchyme which surrounds the tips of the branching 
airways that are in close proximation with the major pulmonary blood vessels 
(Weibel, 2009), resulting in a network of blood vessels that interweave with the 
proximal airway.  This establishes an efficient surface for gas exchange, which is 
further enhanced by the close association between the capillary network and the 
epithelial airway lining (Weibel, 2009).  After 23 generations of airway branching, the 
pulmonary vasculature undergoes an additional 5 generations of branching, 
culminating in the formation of a vast capillary network and the appearance of 
micro-vascular structures around each alveolus (Land, 2011).    
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The lung vasculature is thought to form concurrently by two processes; angiogenesis 
and vasculogenesis.  Angiogenesis is the process by which blood vessels form from 
progenitor endothelial cells, which extend from existing blood vessels from the 
cardiac tissue (Cardoso & Lü, 2006).  On the other hand, vasculogenesis is defined as 
the formation of new blood vessels, derived from differentiated endothelial cells 
coupled by a de novo production of angioblasts that form a primitive vascular 
network (Vailhé et al., 2001).  Vasculogenesis involves the formation of blood vessels 
that are in close proximity to the developing airway epithelium.  This results in the 
formation of a large capillary network that unites blood vessels, leading to the 
complete vascularisation of the lung.  However, how angiogenesis and 
vasculogenesis co-ordinate with each other is unknown.  One school of thought is 
that these two processes converge and ‘fuse’ during mid-late gestation (deMello et 
al, 1997), while other studies suggest that both angiogenesis and vasculogenesis 
occur independently of one another (Hall et al, 2002).  In order to avoid this 
ambiguity, this thesis will simply refer to vascular development of the lung as 
‘vascular growth’. 
Organisation of the vascular tree. 
 
The tightly co-ordinated development between the airway and pulmonary 
vasculature culminates in the formation of a system of three closely related 
branching trees that comprise the adult lung (Weibel, 2009).  These three 
interwoven tubular structure consist of the airway, pulmonary artery/venal and the 
bronchial artery/venal systems (Figure 1.2), which are all packed into the chest cavity 
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at a compressed volume of 6 litres (Land, 2011).  The pulmonary arteries branch in 
parallel with the airways and the bronchial tubules, presumably so that the exchange 
of deoxygenated blood to the alveoli can occur with each generation of branching.  
On the other hand, the pulmonary veins position themselves between the broncho-
arterial units (Weibel, 2009) and mediate the transport of oxygenated blood from 
the lung to the left atrium of the heart.  The bronchial circulatory system forms a 
dense vascular plexus in the airway wall, where the arteries are responsible for 
supplying deoxygenated blood and nutrients to the airway and other lung structures 
(Charan et al., 1984).  The bronchial arteries are derived from the thoracic aorta and 
are distributed around the bronchial glands and coat the walls of the larger bronchial 
tubes and pulmonary vessels (Gray, 1918).  The bronchial vein is established at the 
root of the lung where it forms part of the venous drainage system of the lung, 
which is responsible for supplying part of the deoxygenated blood to the azygos vein 
(right bronchi) and the left superior intercostal vein (left bronchi), while the 
remaining blood is returned to the heart via the pulmonary veins (Charan et al., 
2007).  Embedded within the vascular tree is a complex pulmonary lymphatic 
system, which is an important part of the body’s immune system.  The lymphatic 
system acts to keep the lungs dry, regulates lung fluid level and acts to eliminate 
foreign agents that can penetrate the epithelium (Schraufnagel, 2010).  It achieves 
this through the circulation of lymph in the lymphatic vessels, which is derived from 
the interstitial fluid.  The lymph is circulated around through lymph vessels and 
lymph nodes before emptying into to the subclavian veins, which return this recycled 
blood plasma back to the heart.  The structure of the lymphatic system in the lung is 
12 
 
 
 
of a tubular and saccular nature, allowing them to interweave with surrounding 
blood vessels and the airway itself (Schraufnagel, 2010).  . 
 
 
Figure 1.2.  A resin cast of the lung vasculature.  This interwoven branching network 
consists of the airway (yellow) and the pulmonary arteries (red) and veins (blue).  
Magnified image illustrates the extent of branching and close association between 
the airway and the pulmonary vasculature.  Model and figure originally constructed 
by Weibel (2009). 
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Vascular endothelial growth factor (VEGF); the hallmark of lung 
vasculogenic signalling. 
 
VEGF is a key regulator of vascular growth during embryonic development and its 
significance has been extensively researched.  Originally described for its 
permeability properties (Senger et al., 1983), VEGF acts as a specific endothelial cell 
mitogen.  In mammals, five ligands of VEGF have been identified, of which VEGF-A is 
the best described (referred to henceforth in this thesis).  The primary function of 
VEGF in lung development is to direct growth of the lung vasculature; secretion of 
VEGF from the lung epithelium signals the production of precursor endothelial cells 
(Acarregui et al., 1997; Brown et al., 2001), which are responsible for blood vessel 
formation.  VEGF also acts as a growth factor in mediating the development of ATII 
cells, therefore linking the vascular role of VEGF with that of epithelial 
differentiation.  VEGF has long standing implications in the maintenance of adult 
lung function as it induces the formation of blood vessels upon injury and during 
poor blood circulation in response to oxidative stress achieved through exercise and 
disease.  
 
VEGF is highly expressed in the airway epithelium of the developing lung but is 
initially expressed in the lung mesenchyme and epithelium around E12.5-14.5 and 
then becomes increasingly confined to the epithelium later on during development 
(Gebb & Shannon, 2000).  Vascular signalling occurs through binding of VEGF to its 
specific Receptor Tyrosine Kinases (RTK) on the cell surface, VEGF receptor 1 (VEGFR-
1/FLT1) and VEGF receptor 2 (VEGFR-2/FLK1/KDR).  Upon dimerisation and 
activation of these receptors, signalling induces the upregulation of genes 
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responsible for encoding endothelial proliferation and migration to differentiate into 
vascular tissue (Scott et al., 2010).  Specifically, activation of VEGFR-2 results in the 
activation of the ERK pathway and association with Vascular-Endothelial Cadherin 
(VE-cadherin) (Voelkel et al., 2006).  This association releases phosphorylated β-
catenin to translocate to the nucleus to induce epigenetic up-regulation of the VEGF 
gene and subsequently, protein expression (Skurk et al., 2005).   However, VEGFR-1 
and -2 both differ in their signalling properties (Ferrara et al., 2003).  It is thought 
that VEGFR-2 mediates almost all the known cellular responses to VEGF (Holmes et 
al., 2007), whereas VEGFR-1 has been shown to transduce different VEGF-dependent 
cellular events, which have proven difficult to elucidate (Voelkel et al., 2006).   This 
could be explained by the possibility that VEGFR-1 only becomes active when it is 
heterodimerically bound to VEGFR-2 (Waltenberger et al., 2000).    
 
The importance of VEGF in regulating lung development cannot be understated.  
VEGF gene splicing of mRNA in humans and mice has given rise to several isoforms 
all with varying biological activities (Voelkel et al., 2006).  In mice, the loss of a just a 
single VEGF allele results in lethality around embryonic day 11.5 (E 11.5) (Del Moral 
et al., 2006) and knockouts of both VEGFR-1 and -2 also result in lethality, prior to 
development of the lung capillary plexus (Gebb & Shannon, 2000).  Conversely, 
overexpression of VEGF in lung epithelium causes lung dysplasia, thus indicating that 
regulation of VEGF is vital for normal lung development and function (Zeng et al., 
1998). 
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Hypoxia Inducible factors and the regulation of VEGF-A gene 
expression. 
 
Hypoxia inducible factors (HIFs) are a family of transcription factors that are 
susceptible to changes in oxygen in the cellular environment (Smith et al., 2008) and 
are responsible for the expression of >70 genes required for metabolism and 
apoptosis/survival (Land & Tee, 2007).  There are three HIF isoforms that are 
expressed in the fetal lung (HIF-1, HIF-2 and HIF-3).  Under hypoxic conditions, HIF-1 
was originally discovered bound to the hypoxia response element (HRE) of the 
Erythropoietin (EPO) gene, which regulates red blood cell production (Semenza & 
Wang, 1992).  HIF-1 is highly conserved and its acitvity is tightly governed by oxygen 
homeostasis.  It has a heterodimeric structure, consisting of its α and ß subunit and 
low oxygen enhances HIF activity through stabilisation of the α subunit (Land & Tee, 
2007).  The oxygen-sensing component of HIF-1α is a Prolyl Hydroxylase Domain 
(PHD), which exists within the Oxygen Dependent Degradation Domain (ODDD) of 
the HIF-1α protein (Figure 1.3A).  Upon oxygenation, HIF is highly unstable and the 
hydroxylated prolines on the HIF protein become ubiquitylated by the Von Hippel-
Lindau (VHL) E3 ubiquitin ligase derived from the VHL tumour suppressor, which 
results in the complete degradation of the HIF-1α protein.  VHL syndrome is a rare 
genetically inherited disease which is caused by a mutation in the VHL tumour 
suppressor gene on chromosome 3p25.3 (Wong et al., 2007).  VHL is characterised 
by symptoms such as renal cell carcinoma and angiomatosis, which accounts for 
37.2% of patients presenting with VHL (Wong et al., 2007). 
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As discussed earlier, fetal lung development occurs in hypoxic conditions, where the 
PHD remains inactive and HIF is stabilised due to the fact that hydroxylases and VHL 
proteins are both inhibited in the absence of oxygen (Ziello et al., 2007).   At this 
point, the HIF-1β subunit can bind to the α-subunit at the N-terminal basic helix-
loop-helix (bHLH) and PAS motifs (Crews, 1998) and this newly formed heterodimer 
rapidly translocates to the nucleus (Figure 1.3A, B).  The HIF-1β subunit is an Aryl-
hydrocarbon Receptor Nuclear Translocator (ARNT) that is universally expressed by 
almost all cells, whereas HIF-1α is very lowly expressed under normoxic conditions 
(Shimoda & Semenza, 2011).  Upon nuclear translocation, the HIF dimer binds to 
DNA sequences on the HRE of an associated target gene, such as VEGF-A and 
transcription is sequentially activated through the interaction between the C-
terminal Transcriptional Activation domain (C-TAD) of HIF-1α and the histone 
acetyltransferase, CBP/p300 (Land & Tee, 2007) (Figure 1.3C).  Upon stabilisation at 
low oxygen, HIF ultimately induces the expression of oxygen-independent cellular 
responses and notably the upregulation of the VEGF-A gene.  In the fetal lung, HIF-1α 
expression is localised to the branching airway epithelium (Groenman et al., 2007), 
where its depletion correlates with reduced lung branching moprhogeneis and 
vascular growth (van Tuyl et al., 2005) and its geneteic knockout is embryonic lethal 
at embryonic day (E) 10.5 (Kotch et al., 1999). 
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Figure 1.3.  Nuclear translocation and activation of HIF-mediated VEGF-A gene 
expression.  HIF-1α translocates to the nucleus upon dimerisation with HIF-1ß (A) 
and binds to the HRE of the VEGF-A promoter (B).  This interaction is coupled activity 
of the histone acetyltransferase CBP/p300 on the C-TAD domain of HIF-1α, which 
permits expression of the VEGF-A gene (C).   
 
HIF-2α is also expressed in the airway epithelium and has been reported to serve 
important functions during lung development.  HIF-2α displays the same structural 
affinities as HIF-1α and can also translocate to the nucleus upon dimerisation with 
HIF-1β.  Where HIF-2α varies from its isomeric counterpart is in its pattern of 
expression.  HIF-2α is only expressed in certain tissues (Wiesener et al., 2003) unlike 
HIF-1α, which is widely expressed.  HIF-1α and HIF-2α are closely related and are 
both involved in the transcriptional activity of HRE-dependent genes (Wenger, 2002), 
although the preferential regulation of VEGF by either isoform appears to be 
18 
 
 
 
dependent on individual cell types (Rankin et al, 2008).  Furthermore, phenotypic 
studies of HIF-1α and HIF-2α knockout mice have indicated that both isoforms have 
different functional roles (Holmquist-Mengelbier et al., 2006).  This is further 
indicated by, Eubank et al., (2011), who speculates that HIF-1α and HIF-2α play 
opposing roles in regulating VEGF, whereby HIF-2α acts as an antagonist of VEGFR-1 
function, opposing HIF-1α pro-angiogenic signalling of VEGF secretion.  In the lung 
specifically, HIF-2α expression is strongly associated with the development of 
vascular structures (Groenman et al., 2007) and has also been reported to regulate 
the expression of certain VEGF isoforms in the developing lung (Voelkel et al., 2006).  
However, unlike HIF-1α, it does not regulate VEGF-A in the fetal system as it is only 
expressed in the lung during late embryonic stages (Ahlbrecht et al., 2008).  This was 
established by studies from Compernolle et al., (2002), who demonstrated that 
knockout of HIF-2α caused vascular defects during alveolar septation, which marks 
the transition from the saccular to alveolar phase of lung development at which 
point VEGF-A expression is  reported to decline (Levy et al., 2005; Remesal et al., 
2009). 
 
The final known isoform of HIF is HIF-3α.  It differs in the structural features of its 
isomeric counterparts as it lacks the C-TAD required for transcriptional initiation 
(Hara et al., 2001).  Its expression and function are poorly understood but it is 
postulated that it acts as a repressor of HIF-regulated gene expression (Hara et al., 
2001). 
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The molecular cues that signal airway and vascular growth. 
 
In spite of the ambiguity surrounding development of the lung vasculature, it is 
certain that this process is heavily influenced by cellular and molecular cues (Gebb & 
Torday, 2008), which involve cross-talk between the mesenchyme, airway epithelium 
and the vascular network.  The early phases of lung development rely on the 
activation of angiogenic growth factors and their associated receptors (Han & 
Stewart, 2006), which contribute to the stereotypical fractal patterning of the 
airway.  The maintenance of the mesenchymal-epithelial-vascular bed axis is crucial 
as it dictates the fractal patterning that is diagnostic for normal lung development.  It 
is also necessary for patterning blood vessel growth and differentiation of many cell 
types as well as smooth muscle and cartilage formation (Unbekandt et al., 2008).  
This axis can be severely compromised if disrupted; for example, if there is no 
mesenchymal tissue present, then there are no cellular cues present to induce 
branching of the nearby epithelium (Gebb & Torday, 2008).  Conversely, in the 
absence of epithelium, the mesenchymal cells will die and consequently, the 
vascular networks will perish (Demayo et al., 2002).  This close intimacy is vital for 
complete lung development and also for the sustainment of normal lung function 
(Demayo et al., 2002).  A number of signalling proteins have been shown to 
putatively influence branching morphogenesis as demonstrated by gene studies in 
Drosophila (Metzger & Krasnow, 1999).  However, there are a number of known key 
players that regulate the close association between airway and vascular 
development. 
 
20 
 
 
 
FGF10 is a key inducer of airway outgrowth of the lung epithelium. 
 
Fibroblast Growth Factors are vital in organogenesis as they induce the activity of 
RTKs leading to the proliferation and differentiation of several cell types (Glienke et 
al., 2000) and have been reported to be specifically involved in the formation of the 
epithelium and the vascular system throughout all phases of lung development 
(Sutherland et al., 1996).  In the early phases, FGF1 and 7 both induce airway 
epithelial proliferation (Lebeche et al., 1999) whereas FGF3 and 4 are important in 
mediating post-natal development of the alveoli (Weinstein et al., 1998).  FGF10 in 
particular plays a vital role in lung morphogenesis (Ornitz & Itoh, 2001) and is known 
to play a chemotactic role in epithelial structuring which determines branch 
patterning (Unbekandt et al., 2008).  Originally discovered to be localised in the 
mesenchyme of E14 rat lungs (Yamasaki et al., 1996), several studies have 
demonstrated that FGF10 is closely associated with lung bud formation (Bellusci et 
al., 1997a).  The known role of FGF10 is to determine the length of airway tubules 
and the location of subsequent branch generations which results in primary bud 
formation.  This function appears to share homology with the branchless gene 
observed in Drosophila (Sutherland et al., 1996).  However, FGF10 has also been 
reported to induce secondary budding of lung lobes upon interaction with other 
growth factors which will be discussed later in this chapter.  During development, 
FGF10 is secreted from the mesenchyme and binds to the epithelial-bound receptor, 
Fibroblast Growth Factor Receptor 2 (FGFR2b). Upon activation and dimerisation of 
FGFR2b, FGF10 induces structural changes to the adjacent epithelial cells (Mailleux 
et al., 2001), accompanied with signalling of RTK pathways, promoting proliferation 
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and the outward movement of the endoderm.  This culminates in the elongation of 
the airway towards the FGF10 source (Menshykau et al., 2012; Scott et al., 2010).  
Conversely, inactivation of FGFR2b leads to disruption of this diagnostic bifurcation 
of the airway and the emergence of small epithelial outgrowths which arise 
arbitrarily along the main bronchi (Alber et al., 2009).  The FGF10/FGFR2b 
mechanism has only been demonstrated in vitro (Warburton et al., 2003) but some 
in vivo models have shown that without the FGF10/FGFR2b association, lung 
development would cease (De Moerlooze et al., 2000) and in developmental 
diseases such as LADD (lacrimo-ariculo-dento-digital) syndrome, which is caused by 
mutations that modify the ‘b’ isoform of FGFR2b, the chemotactic influence of FGF10 
is severely compromised (Rohmann et al., 2006).  The role of FGF10 in mediating 
vascular development is unknown although it has been speculated that VEGF-A 
induction may be directly regulated by the FGF10 signalling (Del Moral et al., 2006). 
Sonic Hedgehog (SHH) and Bone Morphogenetic Protein 4 (BMP4) 
control the spatial expression of FGF10. 
 
In addition to FGF10, Sonic Hedgehog (SHH) is thought to play an important role in 
branching morphogenesis, particularly in determining the bifurcating pattern of the 
developing airway epithelium (Menshykau et al., 2012).  Upon induction of FGF10, 
SHH protein is highly expressed in the foregut endoderm from where branching 
morphogenesis commences and it acts as a positive regulator of cell proliferation 
(Bellusci et al., 1997b).  During development, SHH is secreted by the epithelium in 
the distal tips of the airways (Pepicelli et al., 1998).  Its mode of action is to 
reversibly signal to the mesenchyme and bind to its receptor, a transmembrane 
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protein known as Patched 1 (PTC1).  Activation of PTC1 triggers signalling to several 
target genes associated with SHH, which ultimately leads to the repression of FGF10 
signalling.  The resulting repression ‘splits’ the FGF10 signal to promote the next 
round of branching. This ‘inhibition’ is reversed through the activation of Hedgehog 
Interacting Protein 1 (HIP1) in the mesenchyme, which represses epithelial SHH 
signalling, thus allowing FGF10 expression to induce airway elongation (Chuang & 
McMahon, 2003). An illustrative depiction of the SHH signalling mechanism is 
described in Figure 1.4.  Much like FGF10, SHH shares a distinct homology with its 
corresponding hedgehog gene in Drosophila (Miller et al., 2001) and both proteins 
interact with each other indirectly and are essential in facilitating normal airway 
development.  In vivo models of SHH null mutants have been shown to cause severe 
defects in branching morphogenesis and overexpression of SHH reduces FGF10 
expression and the magnitude of distal branching (Menshykau et al., 2012).   
 
Bone morphogenetic protein 4 (BMP4) is another secondary gene induced by FGF10 
expression.  BMP4 is a member of the Transforming Growth Factor β (TGFβ) 
superfamily of proteins whose function has been highly conserved throughout 
evolution (Weaver et al., 1999) and is expressed in both the mesenchyme and the 
distal tips of the airway epithelium. Much like SHH, BMP4 signalling is regulated 
through expression of a specific antagonist, in this case, Noggin, which is transiently 
expressed in the mesenchyme (Weaver et al., 1999).  However, the mechanism by 
which BMP4 regulates lung development remains difficult to elucidate.   Its proposed 
function is to negatively regulate FGF10 thus inhibiting epithelial cell proliferation 
and disturbing branch extension (Hogan, 1999).  While this theory has been 
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demonstrated with in vitro models (Menshykau et al., 2012), Bragg et al., (2001), 
showed that adding BMP4 to lung organ cultures promoted branching 
morphogenesis and epithelial budding,  Examinations of BMP4 expression in early 
lung development have highlighted a potential role for BMP4 in determining the 
structuring of the early lung (Weaver et al., 2000).  Regardless of this ambiguity, 
BMP4 signalling draws several parallels with that of SHH signalling in that they both 
influence FGF10 expression. 
 
Figure 1.4.  FG10 and SHH signalling branching morphogenesis in the fetal lung.  
The left hand-side exhibits the stereotypical FGF10-FGFR2b signalling cascade 
resulting in the elongation of the airway buds.  The right-hand side demonstrates 
secondary budding initiated by SHH regulation of FGF10 signalling through 
interaction with HIP1.  This results in reduced SHH signalling and increased FGF10 
expression in the immediately adjacent regions, allowing secondary budding to occur 
(Cardoso & Lü, 2006). 
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FGFR2b activation induces airway growth through the MAPK pathway. 
 
Signalling of the Mitogen-activated Protein Kinase (MAPK) pathway governs cell 
growth, differentiation and apoptosis (Qiu et al., 2000) and its activity is well-
established in the developing lung.  Upon activation of FGFR2b at the epithelial 
membrane, a complex consisting of the lipid-docking protein, Fibroblast Growth 
Factor Receptor Substrate 2 (FRS2), Growth Factor Receptor-bound Protein 2 (GRB2) 
and Son of Sevenless (SOS) forms (Warburton et al., 2003).  In addition to this, 
FGFR2b also binds a positive tyrosine phosphatase regulator, Src-homology 2 
Domain-containing Phosphatase 2 (SHP2) to FRS2, which is required to fully 
potentiate MAPK activity (Hadari et al., 1998).  The formation of this complex results 
in the catalysis of RAS from its Guanine Diphosphate (GDP) to the Guanine 
Triphosphate (GTP) active form, which enables the RAF serine/threonine kinase to 
induce the Mitogen-activated Protein Kinase Kinase-1 (MEK-1) activation of ERK1/2 
(Land, 2011) (Figure 1.4).  The outcome of this growth-factor mediated signalling 
cascade is potentiated outward growth of the lung airway epithelium towards the 
FGF10 source. 
The PI3K/AKT and mTOR pathways drive vascular signalling of the fetal 
lung. 
 
Much like the MAPK signalling cascade, Phosphatidylinositol 3-kinase (PI3K) 
regulates cell growth, differentiation and survival but is also a key regulator of 
protein synthesis (Taniguchi et al., 2006).  Similarly, activation of PI3K is known to 
occur upon FGR2b dimerisation and interaction with FRS2 (Eswarakumar et al., 
2005).  However, PI3K activity can also be stimulated independently of RTK activity 
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by means of G-protein coupled-receptors and a number of other stimuli 
(Goncharova et al., 2002).  PI3K activation induces the production of 3-
phosphoinositide lipids (PIP3), whose phosphorylation can be reversed by 
Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) activity, 
thereby counteracting PI3K activity (LoPiccolo et al., 2008).  This process is of 
significance as PTEN has been found to be mutated in a number of cancers.  Upon its 
phosphorylation, PIP3 acts as a plasma membrane docking site for proteins that 
contain Pleckstrin-homology (PH) domains (Castellano & Downward, 2011).  One 
such PH-containing protein is the serine/threonine kinase, AKT, also known as 
protein kinase B (PKB).  AKT is an established regulator of cell growth, proliferation, 
metabolism and survival (Manning & Cantley, 2007).  Little is known of a role for the 
PI3K/AKT signalling cascade in regulating fetal lung development but recent evidence 
suggests that a loss of AKT has detrimental effects on normal lung epithelial 
development (Alphonse et al., 2011).   
 
In terms of cell growth, a key downstream target of AKT is the serine/threonine 
protein kinase, the Mammalian Target of Rapamycin (mTOR).  mTOR integrates the 
input from upstream signalling pathways and as such regulates cell growth, motility, 
survival, protein synthesis and transcription (Hay & Sonenberg, 2004).  Activity of 
mTOR itself is sensitive to nutrients, energy metabolism and growth factor signalling 
and disruption of these upstream regulators can have severe implications for the 
role of mTOR in metabolic diseases and cancer (Hay & Sonenberg, 2004).  mTOR 
exists as two distinct complexes; mTORC1 and mTORC2.  mTORC1 is a downstream 
target of PI3K/AKT that is comprised of a Regulatory Associated Protein of mTOR 
26 
 
 
 
(RAPTOR) and a mammalian LST8/G-protein ß-subunit-like protein (Villanueva et al., 
2008).  mTORC1 acts as a regulator of cell growth through activation of Ribosomal 
Protein S6 Kinase Beta-1 (S6K) where phosphorylation at threonine 389 (Thr389) is 
used as an assay to measure mTORC1 activity (Pullen & Thomas, 1997).  On the other 
hand, mTORC2 is composed of a Rapamycin-insensitive Companion of mTOR 
(RICTOR), a TOR complex subunit LST8 (GßL) (Sarbassov et al., 2004) and Mammalian 
Stress-activated Protein Kinase Interacting protein 1 (mSIN1) (Frias et al., 2006), 
where it functions as a key regulator of the cytoskeleton (Sarbassov et al., 2004).  
 
In the context of fetal lung development, the PI3K pathway is essential for up-
regulation of VEGF-A in epithelial cells (Rak et al., 2000), while mTORC1 is thought to 
be the key component that drives vascular signalling as mTORC2 is basally insensitive 
to rapamycin (Land, 2011).  Furthermore, high levels of S6K phosphorylation at 
Thr389 have been observed in the epithelium within the airway bud (Scott et al., 
2010).  This was confirmed by Land & Tee (2007) who identified an mTOR signalling 
motif (TOS) between amino acids 99 and 104 of HIF-1α.  This motif was shown to 
bind to the RAPTOR component of mTORC1, which can complex with HIF-1ß to 
induce nuclear translocation (as shown in Figure 1.3).  Upon shuttling to the nucleus, 
HIF-1α can then interact with its transcriptional co-activator CBP/p300 to initiate 
transcriptional activation of VEGF-A (Land, 2011).  While there is evidence to suggest 
that mTORC1 may act to link the FGF10 induced airway and vascular signalling cues, 
there is another potential key player in this development. 
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SPRY2 antagonises FGF10/FGFR2b signalling in the lung epithelium. 
 
Sprouty is a protein that was originally discovered in the Drosophila genome and was 
shown to antagonise Epidermal Growth Factor (EGF) and FGF signalling in the 
developing trachea (Hacohen et al., 1998).  Four isoforms of mammalian Sprouty 
have been reported (SPRY1, -2, -3, -4). The expression of SPRY1, -2 and -4 is 
widespread in embryonic and adult cells while the expression of SPRY3 is thought to 
be more restrictive (Cabrita & Christofori, 2008).  Each Sprouty protein carries a 
highly conserved cysteine-rich domain on the C-terminus and a tyrosine-containing 
sequence on the N-terminus of the gene (Satoh et al., 2010), which is 
phosphorylated upon FGF signalling (Cabrita & Christofori, 2008).  The cysteine-rich 
domain is the most conserved domain between species (Glienke et al., 2000) and 
mutation of this domain in Drosophila was shown to drastically alter SPRY2 
membrane association (Glienke et al., 2000), thus confirming the importance of 
these functional domains.  In addition to the findings of Sprouty proteins acting to 
restrict growth-factor signalling, they also act as tumour suppressors in a variety of 
cancers (Lito et al., 2009).  For example, in mouse lung epithelium, Minowada and 
Miller (2009) demonstrated that overexpressing the SPRY2 isoform inhibited the 
development of tumours.  This indicates that Sprouty proteins may be of clinical 
significance in the treatment of cancers.   
In the mammalian lung, SPRY2 is expressed in the epithelial tips of the developing 
airways, where it is has been widely reported to function as a negative feedback 
regulator of FGF receptor signalling (Unbekandt et al., 2008) by specifically inhibiting 
the MAPK pathway (Guy et al., 2009) resulting in a repression of lung epithelial 
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migration and proliferation (Cardoso & Lü, 2006).  Additionally, knockout studies of 
SPRY2 report an increase in the extent of epithelial tube branching (Mailleux et al., 
2001) and alteration of airway diameter (Metzger et al., 2008), thus implying SPRY2 
as a key regulator of airway branching.  The mechanism by which SPRY2 achieves this 
negative regulation is complex (Figure 1.5A).  Upon activation of FGFR2b, the 
tyrosine 55 (Y55) residue located on the N terminus of the Spry2 protein, becomes 
phosphorylated by a c-Src Tyrosine Kinase (c-Src) (Guy et al., 2009).  The Y55 residue 
also binds Protein Phosphatase 2A (PP2A), a widely expressed phosphorylation 
regulator in mammalian cells (Lao et al., 2007).  Src-phosphorylation of the Y55 
domain activates PP2A, which causes dephosphorylation of the serine-rich domain, 
thereby promoting the inhibitory hold SPRY2 has over ERK phosphorylation (Guy et 
al., 2009).  Both the c-Src and PP2A phosphorylation events permit the proline-rich 
PXXPXR SRC Homology 3 Domain (SH3) to become exposed on the C terminus.  PP2A 
specifically induces changes in the structure of the serine-rich domain in order to 
facilitate canonical SH3 binding of adapter proteins.  One such adapter protein is 
GRB2, which becomes silenced upon recruitment by the SH3 binding-motif of SPRY2, 
resulting in the inhibition of ERK (Guy et al., 2009) and subsequently limiting 
development of the airway.  SPRY2 has been reported to also act as an adapter 
protein for the E3 ubiquitin ligase, Canonical Casitas B-lymphoma (cCBL), which is 
also a known inhibitor of the ERK pathway. The cCBL tyrosine kinase-binding (TKB) 
motif is conserved between species and all proteins of the Sprouty family, indicating 
its interaction with SPRY2 is important in regulating SPRY2 activation on RTK 
signalling.  Upon Y55 phosphorylation, cCBL binds to the TKB domain of SPRY2 and 
directs ubiquitylation and subsequent destruction of SPRY2 (Guy et al., 2009).  
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However, Lao et al., (2007) showed that cCBL and PP2A compete for binding to the 
Y55 domain of SPRY2 in human embryonic kidney cells (HEK), leading to the 
presumption that both bind to different pools of SPRY2 in the cell.  Another 
hypothesis postulated by Land (2011) suggests that SPRY2 acts as an adaptor protein 
by binding proteins to its SH3 domain before presenting them to cCBL for 
subsequent degradation (Figure 1.5B). 
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Figure 1.5.  Negative feedback regulation of FGF10/FGFR2b-induced ERK activation 
by SPRY2.  A.  FGFR2b stimulation at the cell membrane signals downstream 
activation of ERK through the MAPK signalling cascade, whilst simultaneously 
activating c-Src kinase, which induces phosphorylation of the SPRY2 Y55 motif.  This 
allows the C-terminal PXXPXR (SH3) motif to become exposed.  B. SPRY2 recruits the 
SH3 domain-containing protein, GRB2, to its SH3 binding motif from the MAPK 
signalling cascade and presents it to cCBL on its Y55 domain as described by Land 
(2011).  See text for further details. 
 
 
. 
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Is there a missing link between airway and vascular growth of the fetal 
lung? 
 
While the structure of the lung is vast and complex, it is hard to imagine that a 
structure of such great magnitude can be packed into such a small space in the body, 
yet is still capable of allowing gas exchange to occur.  To get around this, each lung 
branching structure is arranged into a fractal tubular network that persists with each 
generation of branching during fetal development.  This fractal pattern of branching 
follows geometric principles originally established by Weibel & Gomez (1962) and 
the growth of the fractal airway and vascular trees require strict organisation of the 
molecular signals which regulate the magnitude of tree development.  If these 
structures are to develop relative to one another, there must be a mechanism that 
co-ordinates growth of both the airway and vascular trees. 
The negative feedback mechanism by which SPRY2 regulates FGF10 signalling has 
been well documented. Furthermore, it has been recently established that the 
FGF10/FGFR2b/SPRY2 model facilitates airway growth in a time-dependent matter 
(Scott et al., 2010).  This has led to the premise that an airway branching periodicity 
clock exists, which determines the fractal nature of airway branching observed in the 
adult lung.  However, how this process is linked to vascular growth of the developing 
lung remains unknown.  Scott et al., (2010) expanded on the ‘molecular clock’ 
hypothesis by demonstrating a possible mechanism linking the role of SPRY2-
mediated FGF10 signalling to its potential to induce secretion of VEGF-A from the 
epithelium (Figure 1.6).  This mechanism involves silencing of the Tuberous Sclerosis 
Complex (TSC1/2; Hamartin/Tuberin), which is induced through interaction between 
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SPRY2 at Y55 and cCBL, which ultimately results in the downstream activation of 
mTORC1.  TSC2 contains a GTPase-activating protein (GAP) domain that stimulates 
activation of the small G-protein Ras Homolog Enriched in Brain (Rheb), which is a 
potent activator of mTORC1 (Huang & Manning, 2009).  Upon silencing of TSC1/2 by 
the SPRY2-cCBL scaffold, inactive Rheb-GDP can be converted to an active GTP state, 
thereby catalysing the activation of mTORC1.  This allows mTOR to bind to the TOS 
motif on stable HIF-1α protein, enabling VEGF-A gene expression and vascular 
growth to occur.  Given that FGF10 regulation is dependent upon phosphorylation of 
the Y55 residue on the SPRY2 protein, resulting in the sequestration of cCBL and 
silencing of the TSC1/2 complex, this potentially allows SPRY2 to play a pivotal role in 
directing vascular signalling directed through activation of mTORC1 and subsequent 
VEGF-A expression. 
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Figure 1.6.  Proposed mechanism integrating airway growth and vasculogenesis in 
the fetal lung originally described by Scott et al., (2010).  FGF10 expression in the 
mesenchyme induces ‘cleavage’ of SPRY2 in the distal epithelium.  This ‘cleavage’ 
event is accompanied by formation of a complex between Spry2, cCBL and TSC2.  
This interaction silences the TSC1/2 complex permitting catalysis of Rheb-GTP and 
downstream activation of mTORC1, which then binds to the TOS motif of HIF-1α.  
Subsequent transcriptional expression of VEGF is then induced by HIF-1α 
translocation to the nucleus and CBP/p300 interaction (see Figure 1.3), resulting in 
the appearance of vascular structures behind the growing tip of the airway, as 
indicated by the circular structures.  
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Aims and hypothesis 
 
Considering that the development of the lung airway and pulmonary vasculature is 
tightly co-ordinated, it is surprising to learn that the majority of studies of fetal lung 
development are largely confined to examining the signalling cues responsible for 
directing epithelial outgrowth of the airway branching tree.  As a consequence, 
relatively little is known regarding the signalling molecules that trigger development 
of the lung vasculature.  Furthermore, there is little evidence present that 
establishes a candidate responsible for regulating co-ordinated development of both 
the airway and vascular trees.   
One possible candidate that could link airway and vascular growth of the fetal lung is 
SPRY2.  SPRY2 is expressed in fetal lung epithelium throughout development and is 
capable of trafficking to plasma and intracellular membranes upon FGF10 
stimulation (Jesudason et al., 2010).  Scott et al., (2010) established that an increase 
in SPRY2 activity correlated with the inhibition of airway signalling (ERK1/2) and 
activation of mTORC1 in response to FGF10, implying a role for SPRY2 in directing 
the portioning of kinase signals that cue airway and vascular growth of the 
epithelium.  Furthermore, SPRY2 is known to interact with a wide range of proteins, 
including those that are critical for signalling airway and vascular growth (e.g. 
GRB2/TSC2).  This evidence highlights SPRY2 as a potential key orchestrator of co-
ordinated airway and vascular development of the fetal lung. 
Therefore, the aim of this thesis is to test the hypothesis that SPRY2 acts as the 
‘missing link’ that governs co-ordinated development of the airway and vascular 
trees in the fetal lung.  In order to achieve this aim, SPRY2 expression was examined 
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in ex vivo rat FDLE and in vitro HBE cell models in response to FGF10 stimulation. The 
effect of modifying SPRY2 function via overexpression and mutation was examined 
with particular emphasis placed on the effect this had on ERK1/2, mTORC1, HIF-1α 
and VEGF-A expression.  Finally, considering SPRY2 is capable of shuttling from one 
cellular compartment to another, experiments were carried out to ascertain if SPRY2 
directs vascular growth through the epigenetic regulation of vascular genes.  
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Chapter 2 - Materials & Methods 
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Antibodies 
 
Tables 2.1 and 2.2 below list both primary and secondary antibodies used for 
experiments described in this chapter. 
Primary Antibody Species Supplier Dilution 
Factor/Concentration 
Molecular 
Weight 
(kDa) 
ß-Actin Rabbit NEB (4970) 1:5000 (WB) 45 
C-myc Mouse Life 
Technologies 
(46-0603) 
1µg (ChIP) 36 (fused to 
C-terminal 
SPRY2) 
CBP/p300 Mouse Abcam 
(ab14984) 
1:1000 (WB)/2µg (ChIP) 300 
HDAC1 Mouse Abcam 
(ab46985) 
1:1000 (WB) ~55-57 
HDAC2 Rabbit Abcam 
(ab32117) 
1:100 (WB) ~55-60 
HIF-1α  Rabbit Abcam 1:1000 (WB)/2µg (ChIP) 120 
HIF-3α  Rabbit Abcam 
(ab2165) 
1:1000 (WB) ~72-80 
 
Histone H3 Total Rabbit NEB (2650) 1:5000 (WB)/1µg (ChIP) 17 
MAPK (ERK1/2) Rabbit NEB (9102) 1:1000 (WB) Doublet at 42 
and 44 
P84 Nuclear Matrix Mouse Abcam 
(ab487) 
1:2000 (WB) 84 
p70 S6 Kinase Rabbit NEB (9202) 1:1000 (WB) 70 
phospho (Ser10)-
acetyl (Lys14)- 
Rabbit Millipore (07-
081) 
1:1000 (WB) 17 
Phospho MAPK 
(ERK1/2) 
(Thr202/Tyr204) 
Mouse NEB (9106) 1:1000 (WB) Doublet at 42 
and 44 
Phospho p70 S6 
Kinase (Thr389) 
Mouse NEB (9206) 1:1000 (WB) 70 
Sprouty 2 Rabbit Abcam 
(ab50317) 
1:1000/2000 (IHC/WB), 
2µg (ChIP), 1µg (Co-IP) 
 
Doublet at 39 
and 35 
 
Table 2.1. A list of primary antibodies used in this study.  Information provided 
includes the species from which each antibody was derived, the supplier, 
concentration/dilution used for each application and the molecular weight(s) of the 
detected protein.  Acronyms: WB (Western blot), IHC (Immunohistochemistry), ChIP 
(Chromatin Immunoprecipitation), IP (Immunoprecipitation), NEB (New England 
Biolabs). 
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Secondary 
Antibody 
Supplier Dilution 
Factor/Concentration 
Alexa Fluor 555 
Donkey Anti-Rabbit 
Life 
Technologies 
(A31572) 
1:2000 (IHC) 
Anti-Biotin, HRP-
linked 
NEB (7075S) 1:1000 (WB) 
Anti-Mouse IgG, 
HRP-linked 
NEB (7076S) 1:1000 (WB) 
Anti-Rabbit IgG, 
HRP-linked 
NEB (7074S) 1:1000 (WB) 
Table 2.2.  A list of secondary antibodies used in this study.  HRP-linked refers to 
the secondary antibodies being conjugated with the enzyme horseradish peroxidase 
(HRP), to allow for detection of protein by Enhanced Chemiluminescence (ECL). 
Chemicals and reagents. 
 
All Chemicals were obtained from Sigma Aldrich and were made up in deionised 
water (ddH2O) unless otherwise stated.  
Plasmids 
 
The HIF-1α luciferase (HIF-luc) reporter gene was generated as described in Land & 
Tee (2007).  Renilla (pRL) luciferase control reporter vector was obtained from 
Promega (#E2241). PXJ40-FLAG-human(h) SPRY2, PXJ40-FLAG-SPRY2(Y55F), -ve2000 
(non-target [NT]) and SPRY2 small hairpin RNA (shRNA) constructs were kindly 
provided by P. Yusoff and G. Guy (Proteos, Singapore).  Dual-tagged (DT) plasmids of 
wild-type SPRY2 (SPRY2WT), SPRY2C218A and SPRY2C221A were created by and obtained 
from Dr. Claire Scott (University of Dundee).  In order to create a mutant form of the 
cryptic PXXPXR SH3 domain, three prolines at amino acids 304, 307 and 308 
(PTVPPR) were substituted for phenylalanines.  This was achieved by amplifying a 
single of transcript of SPRY2 from HBE cells and using the restriction enzyme, Dpn1, 
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to target and destroy methyl groups allowing the mutant to be distinguished from 
the wild-type (WT) counterpart.  Plasmids were transformed into the Escherichia coli 
(E. COLI) vector and a single colony was selected for plasmid purification. DNA was 
isolated from the plasmid using a Mini-prep kit (Life Technologies; K2100-10) and 
DNA was sequenced against the T7 promoter sequence to establish successful 
mutation.  
HBE cell culture. 
 
Immortalised HBE (16HBE14o-; Cozens et al., 1994) were obtained from Dr. D 
Gruenert, California Pacific Medical Center, San Francisco, CA.  All cells were cultured 
in Dulbecco’s Eagle Minimal Essential Medium supplemented with Ham’s F-12 
nutrient mix (DMEM/F-12) (Life Technologies; #31331-093), 10% (v:v) Fetal Bovine 
Serum (FBS; #F9665) and 50mg.ml-1 Primocin (Source Bioscience; #ant-pm-1).  All 
cultures were maintained at 37°C in a humidified atmosphere containing 21% O2 and 
5% CO2.  Fresh stocks of HBE were brought up to replace those that had been in 
culture for up to 12 weeks (12 passages) and frozen stocks of each cell line were 
created every 2 weeks.  Upon confluency, HBE were washed twice with sterile PBS 
and were digested using Trypsin/EDTA (Life Technologies; #25300054) and once 
detached, the cells were resuspended in 10ml DMEM.  10µl of cell suspension was 
dispensed into a cell haemocytometer (Immune systems; #BVS100) and cells were 
counted 4 times within 4x4 grids, with the average number of cells counted as 
Xx104cell.ml-1.  HBE cells were routinely seeded out at a calculated density of 
3x105cells.ml-1 and would become confluent within 7 days.  Cultures of HBE 
expressing shRNA and/or overexpressed/mutated variants were cultured similarly.  
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Prior to experimentation, HBE cells were supplemented with DMEM containing 2% 
charcoal-stripped serum (#F6765) and 50mg.ml-1 Primocin.  All cells were cultured in 
a MACS VA500 Microaerophilic Workstation (Don Whitley Scientific, Shipley, West 
Yorkshire, UK) equilibrated at fetal pO2 (3%) and 37°C unless otherwise stated 
Creation of stable SPRY2 HBE cell lines. 
 
DNA was purified using a plasmid midi-prep kit (Qiagen; #12145) according to the 
manufacturer’s instructions.  HBE cells were seeded out in a 25cm2 sterile culture 
flask and 10µg of each DNA construct was transfected into the cells using 
Lipofectamine 2000 (Life Technologies; #11668019) according to the manufacturer’s 
instructions.  The transfection mixture was left on for 4 hours before the media was 
replaced with 2% charcoal-stripped DMEM.  Approximately 24 hours after the 
transfection mix was applied, the cells were supplemented with DMEM/F-12 
containing 10% (v:v) FBS, and 50mg.ml-1 Primocin.  For the shRNA and SPRY2 
cysteine mutant constructs, the media was supplemented 1µg.ml-1 of Puromycin 
(Life Technologies; #A11138-03) and 500µg.ml-1 Geneticin (G418; #A1720) 
respectively.  Cells were allowed to grow to form isolated colonies at which point 
they were digested with Trypsin EDTA and each colony was separately seeded into 
75cm2 sterile culture flasks and allowed to grow to confluency.  Cells were routinely 
supplemented with puromycin/G418 coated DMEM/F-12 medium every two days 
and split once per week.  The extent of SPRY2 shRNA/overexpression/mutation was 
assessed by protein and gene expression analysis. 
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Isolation and primary culture of rat FDLE cells. 
 
The preparation and isolation of rat FDLE cells in this study was adapted from a 
method originally described by Dobbs (1990).  Time-mated pregnant female Sprague 
Dawley rats were purchased from Charles River and were housed in the animal care 
facility at Ninewells Hospital. At gestation day 19 (which resembles the late 
pseudoglandular/early saccular phase of fetal lung development), rats were killed by 
cervical dislocation according to Home Office Legislation under The Humane Killing 
of Animals under Schedule 1 to the Animals (Scientific Procedures) Act 1986.  The 
fetuses were removed by caesarean section and decapitated immediately.  The lungs 
were then excised from each fetus and placed in ice-cold sterile Ca2+ and Mg2+ free 
Hank’s Balanced Salt Solution (HBSS; 5.4mM KCl, 0.44mM KH2PO4, 137mM NaCl, 
4.2mM NaHCO3, 0.34mM Na2HPO4 and 5.5mM Glucose, pH 7.4 with 1M NaOH). 
 
The lungs from each fetus were dissected, finely chopped and washed in HBSS to 
remove excess blood and cardiovascular tissue.  The cleaned tissue was then 
resuspended and digested in 15ml of pre-warmed D/T solution (0.012% [w:v] DNase 
I {#DN25} and 0.02% [w:v] Trypsin {T4126} dissolved in 1x HBSS) supplemented with 
10-12 drops of pre-warmed SSDNase (3mg.ml-1 DNase I [w:v] dissolved in 1x HBSS) 
and was rotated for 20 minutes at 37°C.  The tissue was pelleted at 100 x g for 2 
minutes and digestion was repeated a further time.  The digested tissue was 
resuspended in collagenase (0.012% [w:v] DNase I and 0.1% collagenase {CO130} in 
1x HBSS) and was rotated for 15 minutes at 37°C.  After brief centrifugation, the 
supernatant was transferred to a fresh centrifuge tube and the proteolytic acitvity 
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was neutralized by the addition of an equal volume of DMEM (supplemented with 
10% [vol:vol] FBS) and 50mg.ml-1 Primocin.  The supernatant and remaining digested 
tissue were passed through a 100µm sterile cell strainer with trituration through the 
use of a sterile pastuer pipette.  The filtrate was pelleted and the supernatant 
removed leaving two layers of epithelial and non-epithelial lung tissue.  The 
proteolytic activity of the tissue was again neutralised through resuspension of the 
pellet in DMEM and pelleted at 420 x g for 5 minutes.  The pellet was resuspended 
and added to a sterile 75cm2 cell culture flask and was incubated at 37°C, 5% CO2 for 
30 minutes to allow attachment of the lung fibroblast cells. The supernatant was 
then collected and pelleted to preserve unattached cells (FDLE) and the procedure of 
fibroblast isolation was repeated a further time.  After fibroblast tack-down, the 
unattached cells were collected through centrifugation and the pellet was 
resuspended in serum-free DMEM (-FBS) and briefly spun (130 x g for 2 minutes) to 
remove excess fibroblasts, blood and non-epithelial material.  This resuspension was 
repeated until the medium was clear and an epithelial layer was visible.   
 
FDLE cells were quantified and calculated by weight: volume ratio and were seeded 
out at 5mg.ml-1 and 2.5mg.ml-1 in sterile 6-well plates for nuclear protein and RNA 
analysis respectively.  FDLE were cultured at 37°C in a humidified atmosphere 
containing 5% CO2.  After 24 hours, FDLE cultures were supplemented with DMEM 
containing 2% charcoal-stripped serum and 50mg.ml-1 Primocin before being 
cultured at in a MACS VA500 Microaerophilic Workstation at 3% oxygen to simulate 
hypoxia. 
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FGF10 treatment 
 
FGF10 was purchased from Source Bioscience (#ABC144) as a 25µg lyophilised 
powder and was reconstituted in 0.1% Bovine Serum Albumin (BSA) in 1x PBS and 50 
µg.ml-1 FGF10 aliquots were stored at -80°C.  Both FDLE and HBE unless otherwise 
stated were treated with a dose-response range of FGF-10 concentrations consisting 
of 0, 0.01, 0.03, 0.1, 0.3 and 1µg.ml-1 in 2% charcoal-stripped serum.  Cells were 
incubated with FGF10 for 6 hours prior to cell lysis. 
Whole cell lysis 
 
Cell lysis buffer was obtained from Cell Signaling (#9803S) and diluted down from 
10x stock to 1x with ddH20.  A protease inhibitor tablet (Roche; 11697498001) was 
added per 15ml.  All cells seeded in 6-well culture dishes were lysed in 150µl and 
sheared 10-20 times using a 200µl pipette.  Lysates were then pelleted at 14,000rpm 
for 10 minutes in a pre-chilled centrifuge. 
Nuclear lysis 
 
Cell medium was aspirated and cells were twice washed with ice-cold 1x PBS before 
being scraped into 1x PBS containing 10µM MG132 (MERCK; #474790) and pelleted 
at top speed for 5 minutes.  The cell pellet was resuspended in 200µl Cytosolic Lysis 
Buffer (25mM HEPES, 5mM KCl and 0.5mM MgCl2) containing 10µM MG132 and 
sheared 10-20 times before being agitated for 10 minutes in an eppendorf shaker.  
10µl of 10% Nonidet P-40 (NP-40) was added to each lysate to rupture the nuclear 
membrane.  The lysates were shaken for a further 5 minutes before pelleting at top 
speed for 3 minutes.  The supernatant containing the cytosolic fraction was 
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transferred to a separate eppendorf.  The remaining pellet was then resuspended in 
100µl of Nuclear Lysis Buffer (25mM HEPES, 10% [w:v] Sucrose, 350mM NaCl and 
0.01% [v/v] NP-40) containing 10µM MG132, sheared 10-20 times and then 
sonicated for two 10 second bursts at an amplitude of 6 microns.  The lysate was 
then pelleted at top speed for 10 minutes and the supernatant containing the 
nuclear fraction was transferred to a separate eppendorf.   
Bradford Assay 
 
The Bradford Assay is a colorimetric assay that is used to quantify the concentration 
of a protein in a solution at an absorbance of 595nm when the protein binds to the 
acidic solution of Coomassie Brilliant Blue (Bradford, 1976).  Each cell lysate was 
diluted 1:100 in ddH2O and a standard curve was generated by preparing a 
concentration gradient from 10mg.ml-1 BSA, which was used as background 
concentration for the protein lysates.  20µl of Bradford Reagent (Biorad; #500-0006) 
was loaded into each well of a 96-well plate and 180µl of each standard and diluted 
cell lysate was added in duplicate and mixed thoroughly by pipetting.  The 
absorbance at 595nm for each sample was measured using a microplate reader.  The 
absorbance of each BSA standard was plotted linearly and a line of best fit generated 
a ‘y = mx + c’ equation, where the absorbance at 595nm is y, x is the protein 
concentration and c is the y-intercept coordinate generated by the equation.  
Protein concentration of each lysate was calculated using the following equation: 
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X [mg.ml-1] = [(Y-C)/M] x Dilution Factor 
 
The volume required to analyse 30µg of protein by western blot was calculated and 
added to 10µl of protein loading dye (32mM Tris-HCl pH 6.8, 12.5% glycerol, 1% SDS, 
0.05% bromophenol blue) containing 10% β-2-mercaptoethanol. 
Western blotting 
 
Whole cell and nuclear lysates were analysed by SDS Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) using 10% and 12% resolving gels respectively  (373mM 
Tris-HCl [pH 8.8], 10% or 12% Acrylamide Bis [Biorad; #161-0158], 65.6mM APS, 
3.45mM SDS and 0.12% TEMED) and a 3% stacking gel (123mM Tris-HCl [pH 6.6], 4% 
Acrylamide Bis, 65.6mM APS, 3.45mM SDS and 0.12% TEMED).  Nuclear lysates were 
run on a 12% resolving gel in order to resolve lower molecular weight proteins.  Prior 
to loading, lysates were boiled at 95-100°C prior to loading on the gel.  All lysates 
were run with a Precision Plus Protein Kaleidoscope Standard (Biorad; #161-0375) 
and a Biotinylated marker (NEB; #7727) as an additional indicator of protein 
molecular weights.  All gels were run in 1x Running Buffer (190mM Glycine, 24.8mM 
Trizma Base, 173µM SDS) at 150V and were stopped after the blue dye front began 
to run off the bottom of the resolving gel.  Gels were carefully removed and were 
placed in a module in contact with a nitrocellulose membrane.  The transfer module 
was filled with ice-cold 1x transfer buffer (186mM Glycine, 24.8mM Trizma Base, 
20% methanol) and the proteins were transferred onto the membrane for 1-2 hours 
at 100V.  Blots were stained with Ponceau S Solution (#P7170) to identify even 
transfer and loading of proteins across the membrane.  Ponceau was washed with 1x 
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Tris Buffered Saline with Tween (TBS-T; 20mM Trizma Base, 137mM NaCl, [pH 7.6] 
and 0.1% Tween 20) before being blocked in blocking solution (2.5% non-fat 
skimmed milk; Tesco) in TBS-T for 1 hour.  Blots were incubated in primary antibody 
against the protein of interest overnight.  The next day blots were washed 4 times in 
20ml TBS-T for 5 minutes before being incubated for an hour in blocking solution 
containing the corresponding secondary and an anti-biotin antibody required for 
exposure of the biotinylated marker.  Blots were washed 4 times in 20ml TBS-T for 5 
minutes before being exposed onto film using Luminata Classico HRP substrate 
(Millipore; #WBLUC0500) for detection by ECL.  Exposures for every blot were 
carried out at time intervals of; Immediate, 10 seconds, 30 seconds, 1 minute and 
upward in extreme cases.  If required, blots were stripped using 20ml of acid 
stripping buffer (400mM Glycine, 6.94mM SDS, 2% Tween 20, [pH 2.2]) twice for 30 
minutes.  Blots were then washed 3 times with 20ml 1x PBS for 5 minutes and once 
with 20ml TBS-T before being blocked for 1 hour and then reprobed with a primary 
antibody targeting the protein of interest. 
Reporter gene assays. 
 
Cells were seeded out at 3x105cells.ml-1 per well of a 6 well plate and were allowed 
to achieve 60-80% confluency. DNA was transfected into the cells using 
Lipofectamine 2000 according to the manufacturer’s instructions.  The HIF luciferase 
reporter vector (pGL2-TK-HRE) used in this study contains four copies of the HRE (5’-
GTGACTACGTGCTGCCTAG- 3’) derived from hVEGF-A ahead of a Thymidine Kinase 
(TK) promoter complex, which binds RNA polymerase (Figure 2.1).  In tandem, these 
two domains are responsible for regulating the production of firefly luciferase 
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(Phontius pyralis).  On the other hand, the luciferase control reporter vector, pRL 
(Figure 2.1), lacks the HRE and contains a luciferase gene from a different species 
(Sea pansy: Renilla reniformis).  However, it does contain the TK promoter complex 
required for luciferase activity, thus allowing it to be used as a control for 
transfection efficiency.  Each transfection mixture contained a total of 4µgDNA.well-
1, consisting of 0.5µgDNA.well-1 pRL and either 1 or 3.5µgDNA.well-1   HIF-luc used for 
transient SPRY2 construct transfections and for stable cell lines respectively.  
Transfection medium was left on the cells for 4 hours.  The medium was replaced 
with 2% charcoal-stripped medium and cells were placed at either 3% or 21% pO2 
and left for 18 hours.  Cells were lysed and 10µl duplicates of each sample were 
added to a 96-well plate and run on a Fluostar Optima plate reader (BMG Labtech) 
using the Dual-luciferase® Reporter Assay System (Promega, #E1910), which allows 
the activities of firefly and Renilla luciferase activities to be measured 
simultaneously.  The activity of firefly luciferase is measured first for approximately 
one minute upon application of Luciferase Assay Reagent II (LAR II).  The reaction is 
then quenched and the Renilla luciferase activity is measured after addition of Stop 
& Glo® Reagent to the same sample.  For data analysis, means were taken of each 
duplicate and the means generated for firefly luciferase activity were divided by 
those of Renilla luciferase activity. 
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Figure 2.1.  Plasmid maps of the HIF-luc and pRL-luc vectors.  See text for details. 
Acronyms: Fluc (Firefly luciferase), Rluc (Renilla luciferase), Ampr (Ampicillin resistant 
marker domain). 
RNA isolation and quantification. 
 
RNA was lysed from cells using a Nucleospin RNA II Kit (Macherey-Nagel; #740955) 
according to the manufacturer’s instructions.  5µl of RNA was diluted in 495µl of 
nuclease-free H20 in a cuvette and the light absorption of the diluent was measured 
at 260nm and 280nm spectrophotometer.  The concentration of RNA was calculated 
using the following equation. 
 
Total RNA (ng.µl-1) = A260 x dilution factor x 40* 
 
*A260 = 1, corresponds to 40 ng.µl-1 of single stranded DNA or RNA. 
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RNA was routinely checked for DNA and/or protein contamination by measuring the 
ratio of A260 to A280.  A ratio of ≥1.9 was indicative of pure RNA and was deemed 
viable for use in subsequent analyses. 
cDNA synthesis and quantitative real-time polymerase chain reaction 
(qPCR). 
 
1µg of RNA was reverse-transcribed into complimentary DNA (cDNA) using a 
Quantitect Reverse Transcriptase Kit (Qiagen; #205311) according to the 
manufacturer’s instructions.  For the qPCR reactions   qPCR was performed on Rotor-
Gene Q cycler using a Rotor-Gene SYBR Green PCR Kit (Qiagen; #204074).  All cDNA 
samples were diluted 50-fold for use in the qPCR assay.  A standard curve was 
generated form serial dilutions of a designated sample defined as the calibrator, to 
which each sample’s relative gene expression is measured against.  This sample is 
generally an untreated control.  The concentrations of the standard curve consisted 
of 30ng.µl-1, 15ng.µl-1, 7.5ng.µl-1, 3.75ng.µl-1 and 1.875ng.µl-1.  Quantitect Primer 
Assays were purchased from Qiagen for use in the qPCR assay and were diluted from 
10x stock to 1x aliquots.  A list of these primers is provided in Table 2.4. 
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Gene Primer Assay Catalogue # 
Hs_B2M QT00088935 
Rn_B2M QT00176295 
Hs_BNIP3 QT00024178 
Hs_CCND1 QT00495285 
Hs_SPRY2 QT00005495 
Hs_VEGF-A QT01682072 
Rn_VEGF-A QT00198954 
Table 2.3.  List of Quantitect Primer Assays used in the qPCR analysis.  Hs and Rn 
denote primers against Human and Rat species respectively.  
 
A master mix consisting of 12.5µl of 2x Rotor-Gene SYBR Green RT-PCR Master Mix 
(1x) and 2.5µl of Primer was prepared per sample. 15µl of this mixture was 
dispensed into Rotor-Gene PCR tubes and 10µl of standard curve samples and cDNA 
dilutions was added per tube to create a final reaction volume of 25µl. PCR reaction 
conditions were as follows: 95°C for 10 minutes, 95°C for 7 seconds, 60°C for 14 
seconds, followed by an a temperature ramp from 57-95°C where the temperature 
increased by 1°C every 5 seconds.  All samples were run in duplicate.  The 
‘housekeeping’ or normalising gene used for each assay was Beta-2 Microglobulin 
(B2M), which served as an endogenous reference gene as its expression tends to not 
vary between treatments.  The relative expression of the gene of interest (GOI) in 
relation to the ‘housekeeping’ gene was calculated using the ‘delta delta Ct’ (ΔΔCt) 
method, which is derived from the following series of equations (Pfaffl, 2001): 
 
51 
 
 
 
R = 2[Ct sample – Ct control]  
R = 2ΔCt  
R = 2-[ΔCt sample – ΔCt control] 
R = 2-ΔΔCt 
Where R is the relative expression ratio of the GOI and Ct (Cycle threshold) is the 
cycle number at which point the cDNA is exponentially amplified.   ΔCt is given as the 
difference between the GOI and the housekeeper gene and ΔΔCt is the difference 
between the ΔCt of the control sample and the ΔCt of the GOI.  
 
The fidelity of each run was assessed by the efficiency (e) of the corresponding PCR 
assay, which was calculated according to the equation E = 10[-1/slope] (Rasmussen, 
2001), where efficiency values close to ‘1’ corresponded to ‘perfect efficiency’.  The 
fidelity of each assay was also assessed by the correlation coefficient (R2) obtained 
from the standard curve serial dilutions.  This was used to evaluate the linearity of 
each test sample by measuring it against the regression line generated by the 
standard curve and in doing so, provides an indication of the variability between 
each sample.  A value of >0.98 was considered desirable for each qPCR reaction. 
Immunohistochemistry 
 
FDLE were treated with 0.02 and 0.1µg.ml-1 FGF-10 along with an untreated control 
and were left for 2 hours in hypoxia.  Cells were fixed with 4% paraformaldehyde (in 
1x PBS) for 20 minutes at room temperature and were then washed 3 times with ice-
cold 1x PBS.  Cells were blocked for 1 hour in blocking buffer (5% FBS and 0.3% Triton 
X-100 in 1x PBS) were then incubated overnight in antibody dilution buffer (1% BSA, 
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0.3% Triton X-100 in 1x PBS) containing primary antibody against SPRY2 at a 1:1000 
dilution.  To control for non-specific fluorescent staining, identically treated FDLE 
were incubated overnight in blocking buffer containing non-immunospecific FBS 
immunoglobulins.  Cells were treated with the secondary antibody at a 1:2000 
dilution for 1 hour in the dark at room temperature.  Cells were viewed on under oil 
immersion at x 40 objective on a Zeiss Axiovert confocal fluorescent microscope and 
images were obtained using Improvision 5 software. 
Co-immunoprecipitation (Co-IP) 
 
Cells were plated at a density of 5 x 106 cells.ml-1 in 10cm sterile petri dishes and 
were placed overnight at 3% pO2 upon full confluency.  Cells were lysed in 500µl of 
TETN-250 Buffer (25mM Tris-HCl [pH 7.5], 5 mM EDTA, 250 mM NaCl and 1% Triton 
X-100) and were sheared 10-20 times ensure complete lysis.  The lysates were then 
centrifuged at top speed and protein content was quantified by Bradford assay.  
40µg of cell lysate was placed in a fresh eppendorf to be used as a total cell lysate 
representative (TCL).  500µg of the remaining lysate was diluted up to a total volume 
of 300µl with TETN 250 buffer and 50µl of pre-cleared Protein-A-Sepharose beads 
(P3391-1G) were added to each lysate and were incubated at 4°C for 1 hour with 
rotation.  The bead/lysate mixture was then pelleted by centrifugation and the 
supernatant was transferred to a fresh tube.  1µg of SPRY2 primary antibody was 
added to each lysate, which were subsequently incubated at 4°C for overnight with 
rotation. 
The next days, 50µl of pre-cleared Protein-A-Sepharose beads were added to each 
sample and were incubated for a further 3 hours at 4°C with rotation.  The 
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bead/lysate fraction was then spun down by centrifugation and the supernatant was 
discarded.  Each bead pellet was washed for 5 minutes; twice with 1ml of TETN-250 
buffer and twice with 1ml TE Buffer at 4°C with rotation.  After the final wash, the 
beads were resuspended in 50µl of protein loading dye, which was subsequently 
boiled at 95°C for 5 minutes prior to loading on SDS-PAGE gels. 
Chromatin immunoprecipitation assay (ChIP) 
 
Tables 2.5 and 2.6 provide a list of the primers used for ChIP DNA analysis of the rat 
and human VEGF-A promoter respectively.  Fragments listed are upstream of the 
transcriptional start site. 
Rat VEGF-A 
promoter 
fragment 
Forward Sequence  
(5’ to 3’) 
Reverse Sequence  
(5’ to 3’) 
Base 
pair 
size  
-944 to -
633bp 
TCTGCCAGACTCCACAGTG 
(19bp) 
GCAGGCTTTGACTTCCCAAATAG 
(23bp) 
311 
-661 to -
384bp 
GTTTCCGAGGTCAAACAAGC 
(20bp) 
CACACTATACCCAGACACAC 
(20bp) 
277 
-403 to -
124bp 
GTGTGTCTGGGTATAGTGTG 
(20bp) 
GCCACTACTGCGAAATAGAAA 
(21bp) 
279 
Table 2.4.  A list of primers used to analyse regions of the rat VEGF-A promoter. 
 
Human 
VEGF-A 
promoter 
fragment 
Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) Base 
pair 
size  
-1079 to -
882bp 
CCTCAGTTCCCTGGCAACATCTG 
 
GGCACCAAGTTTGTGGAGCTGAG 
 
197 
Table 2.5.  Primers used to analyse regions of the human VEGF-A promoter. 
 
The ChIP assay method in this study largely adopts the protocol provided by 
Millipore with modifications.  Cells were washed twice in ice-cold 1x PBS and then 
were cross-linked by adding 500µl of 1x formaldehyde for 10 minutes.  The 
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formaldehyde was washed off twice with ice-cold 1x PBS and the cells were then 
scraped into 1x PBS containing a protease inhibitor tablet.  Cells were pelleted at top 
speed for 5 minutes and the supernatant wad discarded.  Pellets were resuspended 
in 200µl SDS Lysis buffer (50mM Tris-HCl pH 8.1, 10mM EDTA and 1% SDS, one 
protease inhibitor tablet was added per 15ml), and were left on ice for 10 minutes to 
allow the cells to swell. Each lysate was sonicated ten times at amplitude of 10 
microns with 15 second bursts and 45 second rest periods to prevent overheating 
and DNA denaturation.  This sonication protocol had been verified beforehand for 
use in this study.  The lysates were then pelleted at top speed for 10 minutes and the 
supernatant was placed in a fresh, sterile 2ml eppendorf. 
 
Lysates were the diluted 10-fold in ChIP Dilution Buffer (16.7mM Tris-HCl pH 8.1, 
167mM NaCl, 1.2mM EDTA, 0.01% SDS and 1.1% Triton X-100).  20µl of the diluted 
cell supernatant from one of the lysates was kept to run as a control (input) in the 
subsequent PCR assay.  Lysates were then pre-cleared with 75µl of Salmon Sperm 
DNA/Protein A Agarose-50% Slurry (Millipore; #16-157C) for 30 minutes at 4°C with 
rotation to remove non-specific background.  Agarose was gently pelleted at 
1000rpm for 1 minute and the supernatant was collected and divided into 500µl 
fractions in fresh sterile 1.5ml eppendorfs.  1-2µg of immunoprecipitating antibody 
was added to the designated fraction and was incubated overnight at 4°C with 
rotation.  For a negative and positive control, 1µg of non-immune murine IgG and H3 
antibody were used respectively.   
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The following morning, 60µl of Salmon Sperm DNA/Protein A Agarose Slurry was 
added to each fraction and the fractions were incubated for 1 hour at 4°C with 
rotation to collect the antibody/histone complex.  Agarose was pelleted gently at 
1000rpm for 1 minute and the supernatant was carefully removed by aspiration.  
The protein A Agarose/antibody/histone complex was then washed for 5 minutes at 
4°C with rotation in 1ml of the following buffers in the order listed; one wash in Low 
Salt Immune Complex Wash Buffer (20mM Tris-HCl [pH 8.1], 150mM NaCl, 2mM 
EDTA, 0.1% SDS and 1% Triton X-100), one wash in High Salt Immune Complex Wash 
Buffer (20mM Tris-HCl [pH 8.1], 500mM NaCl, 2mM EDTA, 0.1% SDS and 1% Triton X-
100), one wash in LiCl Immune Complex Wash Buffer (10mM Tris-HCl [pH 8.1], 1mM 
EDTA, 0.25M LiCl, 1% IGEPAL-CA630 and 1% deoxycholic acid) and finally, two 
washes in TE buffer (10mM Tris-HCl and 1mM EDTA, pH 8.0).  250µl of ChIP Elution 
Buffer (0.1M NaHCO3 and 1% SDS) was added to the pelleted protein A 
Agarose/antibody/histone complex, vortexed briefly and then incubated at room 
temperature with rotation in order to elute the histone complex from the antibody.  
The agarose was spun down at top speed for 1 minute and the supernatant was 
collected in a fresh 1.5ml eppendorf.  This step was repeated a further time to 
produce a final combined eluate volume of ~500µl.  20µl of 5M NaCl was added to 
each of the combined eluates.  1µl of 5M NaCl was added to the ‘input’ sample too.  
All samples were incubated at 65°C overnight to reverse the histone-DNA crosslinks.   
 
The following morning, 10µl 0.5M EDTA, 20µl Tris-HCl (pH 6.5) and 2µl of 10mg.ml-1 
Proteinase K was added to each eluate and the samples were incubated for one hour 
at 55°C.  Samples were then boiled at 95-100°C for 10 minutes to denature the 
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Proteinase K.  DNA was extracted from each eluate using a Nucleospin Gel and PCR 
clean-up kit (Macherey-Nagel; #740609) according to the manufacturer’s 
instrcutions.  Binding Buffer NTB (Macherey-Nagel; #740595), which is specifically 
designed to bind SDS-containing lysates to the columns, was used to prevent 
precipitation of SDS in the extraction procedure.  DNA was eluted in a final volume of 
50µl of 5mM Tris-HCl (pH 8.5). 
 
PCR analysis was performed on a Rotor-Gene Q cycler.  5µl of template ChIP DNA 
was run in a 25µl reaction mixture containing 15µl of 2x Rotor-Gene SYBR Green PCR 
Master Mix and 5µl of 10µM primer.  Reaction conditions were identical to the qPCR 
conditions described earlier in this chapter except for the annealing temperature of 
the rat primers (58°C).  PCR reactions were run on a 1% agarose gel with a 100bp 
DNA ladder and gels were viewed under a UV transilluminator.  
Statistical analysis 
 
All values are expressed as means ± standard error (SEM) unless otherwise stated in 
the figure legend.  ‘n’ is the term used to describe the number of independent 
experiments were the number is defined by the number of repeats.  A student’s t-
test was used to analyse paired single treatments.  For multiple comparisons, 
normally-distributed data were analysed by one-way analysis of variance (ANOVA) 
with a Bonferroni’s post-hoc test to allow for comparisons between individual 
treatments.  A P value of < 0.05 was the threshold value for statistical significance.   
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Chapter 3 - Characterisation of SPRY2 
and its epigenetic role in fetal lung 
epithelium. 
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Introduction 
 
FGF10 as an inducer of airway and vascular signalling. 
 
FGF10 is widely regarded as an inducer of airway branching morphogenesis, whose 
signalling is antagonised by SPRY2 expression.  Scott et al., (2010) also established 
that in FDLE, FGF10 amplified HIF-1α activity through the induction of mTORC1 
expression and this signalling cascade was mediated by SPRY2 expression.  This 
augmented VEGF-A gene expression and acted as an effective link between airway 
and vascular growth.  This was supported by studies in fetal lung explants from mice 
bearing the lacZ gene under the control of the angiopoietin promoter, Tie2 (Tie2-
lacZ), that showed discrete induction of vascular genes occurred around regions of 
the explants that had been implanted with FGF10 soaked beads (Figure 3.1).  
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Figure 3.1.  E12 fetal lung explants from Tie2-lacZ mice ±FGF10 stimulation stained 
for lacZ reporter expression.  The degree of Tie2-lacZ expression is indicated by 
regions of blue staining on the explants.   The greyscale images on the left show bead 
localisation and morphogenesis over the course of the 48 hours.  The diagrams 
shown on the right are those same explants after subsequent lacZ staining and 
removal of beads.  The higher magnification images show detail of intense staining 
upon FGF10/PBS stimulation.  The positions of the beads in these explants are given 
as F (FGF10) and P (PBS).  The peripheral mesenchyme (PM) is highlighted (D) in 
order to differentiate it from the epithelium.  Note the lack of blue staining and thus 
Tie2-lacZ gene expression in the Peripheral Mesenchyme (PM) which demonstrates 
that vasculogenesis is strictly confined to the epithelium in these explants.  Data 
originally published in Scott et al., (2010). 
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VEGF-A expression as a measure of vascular growth. 
 
Little is known about the biology of VEGF-A in fetal lung epithelium.  There is a 
wealth of evidence to suggest that the expression of HIF isoforms and oxygen 
concentration are key regulators of VEGF-A expression (Acarregui et al., 1999, 
Rajatapiti et al., 2010).  As discussed in chapter 1,  HIF-1α is expressed throughout 
fetal development and its genetic knockout causes severe vascular defects (Kotch et 
al., 1999).  On the other hand, knockout of HIF-2α does not effect vascular 
development until late alveologenesis (Compernolle et al., 2002).  Taking this into 
account, and the fact that little is known of the function of HIF-3α, HIF-1α is 
considered the major regulator that drives early vascular development and as such 
VEGF-A can be used as an assay  for quantifying HIF-1α activity.  The major finding of 
Scott et al., (2010) showed that the expression of VEGF-A, which is driven by HIF-1α 
induction in the fetal lung, may be linked to the FGF10 airway outgrowth signal by 
SPRY2.  This suggests that SPRY2 is of central importance to the process of vascular 
growth in the lung and may act as a functional link between FGF10 and VEGF-A 
expression.  This chapter aims to establish the basis for this interaction by 
deteremining if SPRY2 is directly involved in the genetic regulation of VEGF.   
Fetal distal lung epithelium as a cellular model of the fetal lung. 
 
Rat FDLE were used in this study to represent the fetal lung ex vivo/in vitro.  Their 
phase of development is within the late pseudoglandular/early saccular stage of lung 
development, where epithelial proliferation is at its maximal level.  Several studies 
have used the FDLE model to study epithelial cell biology.  A publication by Jassal et 
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al., (1991) revealed that FDLE grow and divide readily in culture.  Prior to their 
experiments, FDLE cultures were supplemented with low-serum which this study has 
also replicated, due to the complications in quantifying growth factor signalling 
attributed to normal serum exposure.  Jassal et al., (1991) also stated that FDLE 
growth conditions favoured 3% oxygen, akin to fetal pO2, which is once again 
replicated in this study.  Subsequent studies have examined FDLE cells in the context 
of epithelial ion transport.  This phenomenom has been observed in primary cultures 
of FDLE (Matalon & O’Brodovich, 1999) and a further study by Land and Collett 
(2001), demonstrated the presence of a chloride ion (Cl-) gradient in FDLE.  During 
development, chloride ion Cl- secretion across the lung epithelium osmotically drives 
liquid into the lumen (Olver & Strang, 1974), which provides the distending pressure 
required for normal development of the lung.  At the time of birth, this fluid must be 
reabsorbed and this process is driven by Na+ transport through the epithelial Na+ 
channel (ENaC) (Baines et al., 2001).  These findings are significant as they provide 
strong evidence for the FDLE cell model as a phenotype representative of the fetal 
lung.  While the majority of research based on the FDLE cell model has focused on 
epithelial ion transport, a recent publication examined the significance of airway 
branching morphogenesis using the FDLE model (Scott et al., 2010).  However, there 
have been no studies investigating vascular signalling of the epithelium in the fetal 
lung using the FDLE model.  This chapter aims to identify vascular events which may 
be regulated by interaction between FGF10 and the repressor of airway growth, 
SPRY2. 
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Results 
Sprouty2 exists in the nucleus of FDLE and HBE cells. 
 
Initial characterisation of SPRY2 expression in FDLE was observed in Figure 3.2, which 
shows the epithelial distribution of SPRY2 ±FGF10 stimulation.  SPRY2 is shown to be 
expressed in the cell membrane and endosomal compartments but is also strongly 
observed in the nuclei of these cells. 
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Figure 3.2.  Immunofluorescent staining of SPRY2 in FDLE cells.  Images of cells in 
top panel showing background fluorescence (A) and high brightness contrast setting 
(B) respectively, were probed with non-immunospecific FBS immunoglobulins.  C. 
SPRY2 staining at the cell membrane (M) and the nucleus (N).  Confocal images taken 
at x800 magnification stained with the amino-terminal antibody to SPRY2. Images in 
bottom panel (C) were taken with the same settings as image A.  Images shown are 
representative of 3 independent experiments. 
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Further confirmation of the nuclear localisation of SPRY2 is displayed in Figure 3.3, 
which displays endogenous Spry2 protein abundance in both FDLE and HBE.  SPRY2 
protein was resolved as a double band with molecular weights of approximately 
35.4+/-0.5kDa and 39.3+/-0.6kDa (n = 18), using the same aminoterminal antibody 
used in the immunofluorescene experiments (Figure 3.3A).  Densitometric analysis 
showed that nuclear SPRY2 (nSPRY2) abundance in FDLE was approximately double 
the abundance levels observed in the HBE cell line (Figure 3.3B).  H3 protein 
expression (17kDa) was run as a loading control and as an independent confirmation 
of nuclear fractionation of the lysates blotted. 
 
 
Figure 3.3.  Endogenous nuclear protein expression of SPRY2 in FDLE and HBE cell 
lines.  Cells were maintained at fetal pO2 prior to nuclear lysis and western blot 
analysis.  Blots are representative of 4 independent experiments where error bars 
are x  ± SEM (n = 4). 
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FGF10 induces clearance of the higher molecular weight form of 
nSPRY2 at both fetal and normoxic pO2. 
Western blot analysis was carried out to determine the effect of FGF10 stimulation 
on SPRY2 protein expression.  Figure 3.4 shows the effect of increasing 
concentrations of FGF10 on cytosolic and nuclear SPRY2 protein abundance 
observed in FDLE.  FGF10 induced a concentration dependent decline in the 39kDa 
form of SPRY2 in both fractions, with no apparent change in 35kDa abundance.  This 
observation was also independent of pO2.  ß-Actin and H3 were blotted as loading 
controls for the cytosolic and nuclear fractions respectively. 
 
 
Figure 3.4.  Effect of increasing FGF10 stimulation upon SPRY2 protein abundance.  
Cells were maintained and FGF10 treated at both fetal and normoxic pO2 prior to 
subsequent lysis and analysis by western blot.  Blots are representative of a 
minimum of 5 independent experiments. 
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Densitometric analysis of the effect of FGF10 on the ratio of nSPRY2 39:35 kDa 
protein abundance is shown in Figure 3.5.  The FGF10-induced loss of the 39kDa 
form of nSPRY2 was shown to be of very high statistical significance. 
 
Figure 3.5.  Ratio of nSPRY2 protein abundance in response to increasing FGF10 
concentration.  Asterisks denote statistical significance (P < 0.05; ANOVA, Bonferroni 
post-hoc test) when compared with the untreated control (0µg.ml-1 FGF10).  Error 
bars are x  ± SEM (n = 4). 
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FGF10 evoked clearance of nSPRY239kDa correlates with H3 phospho-
acetylation. 
 
Figures 3.2 and 3.3 established the nuclear localisation of SPRY2, with the latter 
figure demonstrating co-expression with H3.  Therefore, further investigations into 
the role of SPRY2 as a potential regulator of gene expression were undertaken.  For 
the purposes of this study, the serine 10 (S10) and lysine 14 (K14) residues of H3 
were selected as these residues are known to respond to growth factor stimulation 
(Mahadevan et al., 1991) and are both involved in permitting transcription and cell 
division (Prignet & Dimitrov, 2003; Nowak & Corces, 2004).  HDAC1 and HDAC2 
activity was also examined as their functions are linked to transcription (Miller et al., 
2010) and should also serve as a reverse measurement of S10 phosphorylation and 
K14 acetylation.  Figure 3.6 shows the effect of increasing FGF10 concentration on 
H3 phospho-acetylation and HDAC activity represented by both HDAC1 and 2 
expression.  Increasing FGF10 concentration induced an increase in phosphorylation 
and acetylation of the Serine 10 and Lysine 14 residues of Histone H3 respectively.  
This also correlated with a decline in HDAC1 and HDAC2 protein abundance upon 
increasing FGF10 titration, coupled with the complete loss of nSPRY239kDa. 
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Figure 3.6.  Effect of FGF10 concentration on H3 phosphorylation and acetylation in 
FDLE cells.  Cells were treated as described in Figure 3.4.  Blots are representative of 
4 independent experiments. 
 
Figure 3.7 shows densitometric analysis illustrating the increase in H3 phospho-
acetylation with increasing FGF10 concentration (Figure 3.7A) and the negative 
association between H3 phospho-acetylation and with nSPRY239kDa:35kDa abundance 
(Figure 3.7B).  There is an increased trend in H3 phospho-acetylation with increasing 
FGF10 stimulation.  Although this association is not statistically significant (P = 0.101; 
ANOVA) across treatments, there is statistical significance observed between the 
highest FGF10 dosage and the untreated control (Figure 3.7A).  The loss of 
nSPRY239kDa is associated with an increase in FGF10 concentration and H3 phospho-
acetylation (Figure 3.7B). 
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Figure 3.7.  Densitometric analysis of the relationship between Histone H3 
phospho-acetylation and nSPRY239:35kDa upon increasing FGF10 concentration. A.  
Asterisks denote statistical significance (P < 0.01; student’s t-test) relative to the 
untreated control (0µg.ml-1 FGF10).  B.  Association between H3 phospho-
acetylation: total H3 and nSPRY239:35kDa protein abundance. Values above each plot 
represent the FGF10 concentration (µg.ml-1).  Measurements are x  ±SEM (n = 4).   
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FGF10 induces a trend towards increased SPRY2 and VEGF-A gene 
expression. 
 
Having established the response of nSPRY2 to FGF10, qPCR assays were performed 
to assess the effect of FGF10 concentration on gene expression levels of SPRY2 and 
the major regulated gene product of HIF-1α , VEGF-A.  Figure 3.8 shows the outcome 
of increasing FGF10 concentration upon SPRY2 and VEGF-A gene expression in FDLE. 
Both SPRY2 and VEGF-A mRNA tended to increase with mid-range concentrations of 
FGF10 but failed to reach statistical significance.  
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Figure 3.8. FDLE gene expression levels of SPRY2 and VEGF-A in response to 
increasing FGF10 concentration.  FDLE cells were seeded out at 2.5mg.ml-1  per well 
of a 6 well plate and were used for RNA. A. Values generated were measured over 
B2M expression levels and represent fold change over the 0µg.ml-1 FGF10 response.  
Error bars are ±SEM of fold change (n = 4).  Melt curve representatives for the SPRY2 
(B), VEGF-A (C) and B2M (D) gene are provided where dF/dT is the measure of the 
rate of change of fluorescence.  Each line of the melt curve represents cDNA 
template of each sample and also the standard curve generated for the qPCR assay.  
Melt curves each provide a single peak indicating amplification of the desired gene.  
Average efficiency and R2 values for each gene analysed are provided with the 
corresponding melt curve (n = 4). 
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SPRY2 and CBP/p300 bind to distal regions of the VEGF-A promoter 
that contain GC-Rich domains. 
 
Figures 3.6 and 3.7 established a correlation between the loss of nSPRY239kDa and an 
increase in phosphorylation and acetylation of H3.  Following on from this 
observation, ChIP assays were performed to assess potential role for SPRY2 in 
facilitating gene expression.  To link this to the hypothesised role of SPRY2 in 
regulating vascular growth, regions of the VEGF-A promoter were assessed for the 
affinity of SPRY2, HIF1-α and its co-activator CBP/p300 to bind to these regions. A 
schematic of the rat VEGF-A promoter is shown in Figure 3.9 listing the key binding 
domains that were selected for analysis.  A list of the primers that flank these regions 
and their corresponding molecular weights are provided in Table 2.1. 
 
Figure 3.9. Schematic of the rat VEGF-A promoter displaying the key regulatory 
domains assessed for binding affinity in the ChIP assays.  Amplified regions 
upstream of the transcriptional start site (arrow) are shown in grey. 
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The regions of the VEGF-A promoter that were selected included HRE, a Signal 
Transducer and Activator of Transcription 3 (STAT3) binding domain and a heavily GC-
rich domain further downstream on the promoter.  As stated earlier, HIF-1α and 
CBP/p300 form a complex within the nucleus that facilitates gene expression during 
fetal lung development.  Therefore, this experiment looked to determine if nSPRY2 
was capable of interacting with the VEGF-A promoter and if this altered HIF-1α and 
CBP/p300 binding.  The affinity for SPRY2 (A), HIF-1α (B) and CBP/p300 (C) to bind to 
regions of the VEGF-A promoter in response to increasing FGF10 concentration is 
shown in Figure 3.10.  SPRY2 predominantly bound to regions of the VEGF-A 
promoter which contain GC-rich elements (Figure 3.10A).  The affinity for SPRY2 to 
bind at these regions appeared to be independent of FGF-10.  A weak interaction was 
also observed with the region of the promoter containing the HRE. HIF-1α 
surprisingly showed very weak binding affinity to the HRE on the promoter but this 
could be FGF10 regulated as a band was observed in the 0.1µg.ml-1 lane (Figure 
3.10B).  HIF-1α appeared to bind more strongly downstream of the HRE in a region 
known to contain a functional STAT3 binding site.  The histone acetyltransferase and 
the HIF transcriptional co-activator, CBP/p300, was also found to bind strongly to this 
same region with increasing FGF10 concentration. (Figure 3.10C)  No observation was 
made of CBP/p300 binding to the HIF consensus site (data not shown).  Histone H3 
ChIP samples were run with all test samples and primer sets as a positive control for 
the assay to demonstrate the fidelity of the ChIP assay technique) and binding was 
observed at all regions of the VEGF-A promoter. 
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Figure 3.10.  ChIP assays showing SPRY2, HIF-1α, CBP/p300 and Histone H3 
interacting with distal regions of the VEGF-A promoter.  SPRY2 was shown to bind 
strongly to the GC-rich domain of the VEGF-A promoter (A), accompanied by binding 
of CBP/p300 to this same region (B).  Binding of HIF1α to the HRE of the VEGF-A 
promoter was weakly observed (C).  Non-immune murine IgG and H3 chipped DNA 
(D) were run as negative and positive controls for all primer sets respectively in the 
qPCR reaction.  qPCR reactions were run on 1% agarose gel  and were stained with 
ethidium bromide.  Molecular weights of bands observed are 311bp (-944 to -
633bp), 277bp (-661 to -384bp) and 279bp (-403 to -124bp).  Results shown are 
representative of 4 independent experiments.   
 
A 
B 
D 
C 
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Discussion 
 
Previous studies of the cellular distribution of SPRY2 in fetal and adult lung 
epithelium describe it as being exclusively in the endosome, where it migrates to the 
plasma membrane in response to RTK activation by growth factors (Lim et al., 2000, 
2002), such as FGF10.  This chapter provides evidence that SPRY2 exists in the 
nucleus of both fetal and adult lung epithelial cells as shown in Figure 3.2 and 
subsequent figures of nuclear protein abundance.  This corroborates with two other 
observations of nSPRY2 in developing neural tissue (Aranda et al., 2008; Hausott et 
al., 2012).  Moreover, the major regulator of SPRY2 function in the fetal lung, FGF10, 
induced vascular signalling in intact fetal lungs as demonstrated in Figure 3.1, 
suggesting interplay between FGF10, SPRY2 and vascular development.   
 
SPRY2 protein was resolved as two distinct double bands by SDS-PAGE and this is in 
accordance with previous studies (Chandramouli et al., 2008; Medina et al., 2011).  
However, other studies have observed multiple bands of SPRY2 occurring (Lao et al., 
2006; Edwin et al., 2009), while another study recorded only a single 35kDa band 
(Fritzsche et al., 2006).  Surprisingly, the majority of these studies fail to 
acknowledge the exact molecular weights of both these bands.  In this study, SPRY2 
was resolved at molecular weights of approximately 39 and 35kDa, where the 39kDa 
form was cleared upon increasing FGF10 stimulation and the 35kDa was unaffected.  
This is acknowledged by Lao et al., (2006), who stated that FGF stimulation favours 
the faster migrating band.  However the mechanism by which the loss of the higher 
molecular weight form of SPRY2 occurs is currently unknown.   
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Scott et al., (2010) postulated that this mechanism may be ‘proteasomal cleavage’ 
after conducting experiments using the protease inhibitor MG132, through which 
they found that MG132 stabilised the SPRY2 doublet in the presence of FGF10.  
Furthermore, there is presently no function tied to either of the two forms of SPRY2, 
although a number of post-translational modifications are implicated.  Impagnatiello 
et al., (2001) postulated that the presence of the higher molecular weight form of 
SPRY2 is the result of phosphorylation as it disappears with phosphatase treatment.  
Although the data for this is not shown, this observation allowed Lao et al., (2007) to 
speculate that the higher molecular weight form is related to the serine-rich domain, 
which is known to become dephosphorylated upon binding of PP2A, a protein 
phosphatase.  Lao et al., (2007) also established that SPRY2 was predominantly 
phosphorylated on specific serine residues which are dephosphorylated upon FGF 
stimulation.   
 
Another post-translational modification that may mechanistically facilitate the 
FGF10-induced loss of SPRY239kDa is palmitoylation; a process that regulates 
subcellular trafficking of proteins to the cell membrane and other cellular 
compartments upon recruitment of fatty acids (e.g. palmitate) via a liable thioester 
bond to the cysteine residues on proteins (Salaun et al., 2010).  SPRY2 itself contains 
an unusually large number of cysteine residues making it a likely candidate for 
palmitoylation and experiments conducted by Impagnatiello et al., (2001) 
established that SPRY2 is indeed anchored to the membrane by palmitoylation.  
However, this study does not factor in which form of SPRY2 is palmitoylated, nor the 
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fact that growth factor signalling also plays a role in promoting membrane trafficking 
of SPRY2 (Lim et al., 2000).     
 
The results presented here show that nSPRY239kDa form is sensitive to FGF10 
stimulation and that its loss is accompanied by an increase in H3 phospho-
acetylation and thus gene expression.  This would suggest that the ‘full-length’ form 
of SPRY2 acts to repress gene expression and this effect is relieved by FGF10 
stimulation.  Taking into account the various post-translational modifications SPRY2 
has been suggested to undergo, it is known that FGF10 induces c-Src 
phosphorylation of SPRY2 at its Y55 domain (Li et al., 2004; Scott et al., 2010).  In 
doing so, this initially activates SPRY2, which may explain the initial induction in 
SPRY2 protein abundance observed at 0.01µg.ml-1 FGF10 (Figure 3.5).  As FGF10 
concentration increases, this causes the 39kDa form of SPRY2 to translocate to the 
cell membrane, possibly in accompaniment with palmitoylation of the unusually 
large number of cysteine residues.  This permits phosphorylation and acetylation of 
H3 and the unwinding of DNA leading to the expression of genes.  This hypothesis 
appears to be supported by the evidence presented in Figures 3.6 and 3.7, which 
both show that H3 phosphorylation and acetylation were significantly induced with 
increasing FGF10 concentration.  This was matched by a decline in the loss of HDAC1, 
HDAC2 and also the clearance of SPRY239kDa.  Interestingly, the expression of the 
35kDa form of SPRY2 persists in the nucleus and is unaffected by FGF10 stimulation, 
suggesting that this form of SPRY2 may function in the nucleus in some way. 
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Gene expression occurs in the nucleus through the catalysis of histone proteins, 
which promote unwinding of DNA.  Histones are arranged into octomeric structures 
known as nucleosomes.  The nucleosomes are tightly compacted into chromatin 
fibres which restrict the interaction of proteins with the packaged genomic DNA, 
leading to implications on cellular processes such as transcription and cell division 
(Hans & Dimitrov, 2001).  Each histone contains an N-terminal tail domain which 
protrudes from the nucleosomal surface and is subject to a raft of post-translational 
modifications such as acetylation, methylation, phosphorylation and ubiquitylation 
(Hans & Dimitrov, 2001).  Specifically, phosphorylation of the serine 10 (S10) residue 
on H3 has been extensively described as a key inducer of transcriptional activation 
and chromosomal condensation (Lo et al., 2000).  Its activity is also known to 
dramatically increase upon stimulation of the MAPK pathway (Clayton & 
Mahadevan, 2003), whose signalling is induced by FGF10 expression.   Interestingly, 
the S10 and  lysine 14 (K14) residues are in close proximation on the H3 tail (Lo et al., 
2000) and it has been reported that S10 phosphorylation favours K14 acetylation as 
it abolishes acetylation and methylation of the lysine 9 residue of H3  (Bazer et al., 
2012).   Histone acetyltransferases (HAT) are enzymes that specifically target the 
lysine residues on the amino-terminal tail of histones.  They function to neutralise 
the positively charged histones thereby reducing the interaction of the N termini on 
the histone tails with the negatively charged phosphate backbone of DNA.  
Acetylation of histones promotes gene expression; recombination and DNA damage 
repair (Wang et al., 2012a).  Acetylation however, can be counteracted by Histone 
deacteyltransferase (HDAC) activity.  HDAC enzymes function to restore the positive 
charge to the histones, thereby strengthening the interaction between the histones 
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and the DNA, thus conserving the condensed structure of chromatin.  HDAC1 and 
HDAC2 belong to the Class I HDACs which are expressed ubiquitously in a variety of 
repressor complexes and have been extensively used in tumourigenic studies 
(Wilting et al., 2010).  In lung development specifically, the loss of HDAC1/HDAC2 
has been shown to correlate with reduced airway development (Morrisey, 2012).  
The correlation observed in Figures 3.6 and 3.7 suggests that activation of SPRY2 by 
FGF10 is required for phosphorylation and acetylation of H3 to catalyse the 
unwinding of DNA from the nucleosome, and like SPRY2, the extent of unwinding 
appears to be affected by FGF10 concentration.  Similarly FGF10 appears to down-
regulate HDAC1 and HDAC2 expression as it amplifies phospho-acetylation of H3 and 
induces putative membrane translocation of SPRY239kDa.  However, the expression of 
nSPRY235kDa is sustained thus implicating a potential role in regulating transcriptional 
activation of genes.   
 
FGF10 appears to induce vascular signalling (Figure 3.1, Scott et al., 2010) and has 
been reported to do so through mTORC1 activation (Scott et al., 2010).  However, 
FGF10 stimulation only induced an increased trend towards increased VEGF-A and 
SPRY2 gene expression before a decline in expression is observed at 1µg.ml-1 FGF10 
(Figure 3.8).  These observations are in agreement with Acosta et al., (2001) and 
Scott et al., (2010), who showed that FGF10 induced SPRY2 mRNA expression and 
VEGF-A secretion in the fetal lung respectively.  It should also be noted that there 
were difficulties in measuring gene expression due to the variability in housekeeper 
gene expression.  The housekeeper gene used for this experiment was B2M, where 
levels of expression were found vary between samples and the lack of statistical 
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significance in the data may have arisen through difficulties in quantifying corrective 
gene expression levels.  To quality control this, 18S ribosomal RNA (18S) was used as 
a replacement housekeeper gene.  However expression levels of this gene similarly 
fluctuated between samples and independent experiments.  This observation 
requires further investigation in order to select a viable housekeeper gene with 
which to quantify gene expression in FDLE, if indeed, it is possible. 
 
The anatomical evidence presented by Scott et al., (2010) in Figure 3.1 also indicates 
that FGF10 is a pro-vasculogenic growth factor of fetal lung development.  FGF10 
localisation appears to induce vascular differentiation of the peripheral mesenchyme 
in addition to the epithelium.  Studies from Bellusci et al., (1997a) demonstrated a 
technique whereby the endodermal layer surrounding the mesenchyme was 
removed using a trypsin/pancreatin solution.  This allowed closer observation of 
morphological changes of the airway bud and had this technique been applied to the 
experiment in Figure 3.1, then there would be a potential to closely observe the 
morphology of the epithelium in response to localised signalling of FGF10. 
 
The ChIP assays conducted in Figure 3.10 show that CBP/p300, HIF-1α and SPRY2 are 
capable of interacting with the VEGF-A promoter.  CBP/p300 and SPRY2 bind 
strongly to the GC-rich regions of the VEGF-A promoter suggesting that there may be 
a key functional domain at these GC-rich regions of the promoter.  Given its close 
proximity to the transcriptional start site, it is possible that SPRY2 and CBP/p300 
could act upon the transcriptional start site on the gene, where SPRY2 would act to 
antagonise the catalytic function of CBP/p300 to initiate gene expression.  These 
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‘CpG’ islands are also susceptible to methylation and as a consequence, the 
promoter can be held silent and gene expression is inhibited.  (Bird, 2002).  Within 
the GC-rich domains themselves reside the binding sites for the Specificity Protein 1 
and 3 (Sp1, Sp3) transcription factors (Pagès & Pouysségur, 2005).  Sp1 and its 
repressor Sp3 have both been reported to regulate VEGF and consequently 
angiogenic signalling (Pagès & Pouysségur, 2005).  Given the ability of SPRY2 to 
interact with other proteins as alluded to in Chapter 1, it could be possible that 
SPRY2 may be involved in regulating the recruitment of transcription factors, such as 
Sp1/3, to bind to the VEGF-A promoter.  
Conclusions 
 
The data presented here demonstrates the unique observation that SPRY2 is present 
in the nucleus of the developing lung epithelium where it acts to regulate gene 
expression.  In the nucleus, FGF10 induces the loss of the nSPRY239kDa and this is 
accompanied by an increase in H3 phospho-acetylation, which catalyses the 
unwinding of the DNA from its histone core, thus promoting gene expression.  The 
data also shows SPRY2 interacts with CpG-rich domains of the VEGF-A promoter.  
Given its close proximity to the transcriptional start site, nSPRY239kDa may act to 
antagonise the transcriptional activation of VEGF-A, which is relieved by FGF10-
evoked clearance of ‘full-length’ SPRY2.  This stimulation can then permit growth of 
the vasculature as observed in the fetal mouse lung explants, which is also indicated 
by an increased trend in VEGF-A gene expression.  Therefore, this study suggets a 
novel role for SPRY2 in the nucleus of fetal lung epithelium where it functions within 
the VEGF-A promoter to regulate events that promote vasculogenic gene expression. 
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Chapter 4 - The effect of modifying SPRY2 
protein function on airway and vascular 
signalling in HBE cells. 
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Introduction 
 
Regulation of SPRY2 function – the Y55 domain. 
 
Chapter 3 demonstrated that SPRY2 is present in the nucleus and is capable of 
interacting with the VEGF-A promoter and so links the FGF10 stimulus to vascular 
signalling.  As discussed in Chapter 1, FGF10 activates SPRY2 by inducing 
phosphorylation of its Y55 residue via c-Src kinase activity (Li et al., 2004; Guy et al., 
2009).  Src-phosphorylation of Y55 also promotes PP2A-induced dephoshorylation of 
two serine residues within the serine-rich domain (Ser115 and Ser118), which exposes 
the cryptic proline-rich SH3-binding motif (Lao et al., 2007) at the C-terminal end.  
Many studies have demonstrated that activation of the Y55 phosphorylation residue 
is vital for SPRY2 to function (Fong et al., 2003; Chitra et al., 2010), as it is capable of 
binding the E3 ubiquitin ligase, cCBL, which is thought to regulate levels of SPRY2 in 
the cell (Hall et al., 2003).  Thus, it would appear that the Y55 residue is clearly rate-
limiting for SPRY2 activation.  Mason et al., (2004), demonstrated that c-Src failed to 
induce tyrosine phosphoryaltion of SPRY2 upon mutation of the Y55 residue, which 
also subsequently abolished interaction of SPRY2 with cCBL.  Y55 mutation was also 
shown to reduce the capability of SPRY2 to interact with other molecules and 
ultimately hinder its characteristic function of inhibiting RTK signalling (Chitra et al., 
2010). 
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The cysteine-rich domain. 
In contrast to the Y55 tyrosine kinase phosphorylation domain, little is known of the 
function of the Cysteine-rich Domain (CRD) located near the C-terminus on SPRY2.  
One function assigned to this region is Cys-palmitoylation and subsequent 
membrane translocation of SPRY2 (Impagnatiello et al., 2001).  Lim et al., (2002), 
expanded on this hypothesis by demonstrating that a mutant of SPRY2 (R242D) 
resulted in its failure to translocate to the membrane, coupled with its failure inhibit 
ERK signalling.  Subsequent studies have continued to demonstrate the 
compromised ability of SPRY2 to interact with other proteins and its failure to inhibit 
ERK upon mutation of the CRD (Nonami et al., 2005; Cabrita et al., 2006).  However, 
the true role of the CRD with respect to SPRY2 function remains ambiguious, a fact 
acknoweldged by the in-depth review of SPRY2 from Guy et al., (2009). 
Recent bioinformatic analysis from collaborators of our lab has unveiled two 
cysteines within the CRD of SPRY2 (C218 and C221), which were shown to be highly 
conserved among the SPRY isoforms and across species with homology observed as 
far back as the Drosophila lineage (Figure 4.1).  These cysteines have also been 
shown to share partial homology with the Ran-binding protein Zinc finger domain 
(RanBP2).  This homology was discovered by entering the SPRY2 amino acid 
sequence into the protein database program PROSITE (http://prostieexpasy.org/), 
which identifies domains of unrelated proteins that share a similar amino acid 
sequence with that of the input protein.  The program provides a value which is used 
to calculate a similarity score for any alignment between the input protein sequence 
and that of an unrelated protein sequence.  In this case, the value generated by the 
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program gave a score of 6.514 for Zinc finger RanBP2 relative to the the amino acid 
sequence of SPRY2 (Figure 4.1A), albeit with a low confidence level rating and low  
hit level. 
The term ‘zinc finger’ (ZnF) was used to describe a 30-amino acid sequence motif 
originally discovered in the transcription factor TFIIIA from Xenopus laevis.  This 
motif was found to form an independent DNA-binding mini-domain folded around a 
centralised zinc ion, with a tetrahedral arrangement of cysteine and histidine metal 
ligands (Miller et al., 1985).  The arrangement of this domain is such that, a series of 
adjacent ZnFs protrude and ‘grip’ the DNA and other interacting particles (hence the 
term finger) and they have subsequently been discovered in many eukaryotic DNA 
binding proteins (Klug & Schwabe, 1995).  ZnFs themselves are structurally diverse 
and are classified as a series of fold groups, based on the strucutral properties 
around the zinc-binding site. The best studied of these fold groups are the  Cys2-His2 
ZnF, which is commonly found in mammalian transcription factors (Krishna et al., 
2003) and the zinc ribbon fold. 
Ran-binding proteins (RanBP) themselves are involved in regulating receptor-
mediated transport between the nucleus and the cytoplasm (Steggerda & Paschal, 
2002), where the ZnF protrusions act to bind DNA, RNA, proteins and other small 
molecules. The ZnF of RanBP were first identified in the nuclear export protein  
RanBP2.  The ZnF are arranged by the zinc ribbon fold configuration, whereby ZnF 
fold into a structure composed of two ß-hairpin strands, which sandwhich a zinc ion 
(Gamsjaeger et al., 2007).   The partially-shared cysteine homology that exists 
between RanBP2 and SPRY2, suggests that the CRD of SPRY2 may also harbour a 
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potential ZnF DNA-binding domain, thus providing further evidence that SPRY2 
functions in the nucleus as described in Chapter 3. 
 
Figure 4.1. Amino acids 209-221 spanning the CRD  (highlighted in yellow) of SPRY2 
are conserved amongst SPRY isoforms (A) and among species (B), whilst also 
occuring within the RanBP2 sequence (highlighted in green).  Cysteines 218 and 
221 (highlighted in red) were selected for mutation in this study. 
 
 
 
 
A
B
hSPRY1:  LACNRQCLCSAESMVEYGTCMCL 
hSPRY2:  WICDKQCLCSAQNVIDYGTCVCC 
hSPRY3:  WLCNQRCLCSAESLLDYGTCLCC 
hSPRY4:  WVCNQECLCSAQTLVNYGTCMCL 
hRanBP2: WDCSV CLVRNEASA  TKCIAC 
 
Drosophila (Fruit fly):        
            WVCNKTCLCSAESVIDYASCLCC 
Danio rerio (Zebra fish):    
 WMCGRRCVCSATSAMDYVTCVCC 
Xenopus (African clawed frogs):  
 WICDKQCLCSAQEVVDYGTCACC 
Gallus gallus (Chicken):  
                            WICDKQCLCSAQNVVDYGTCVCC 
Mus musculus (Mouse):  
           WICDKQCLCSAQNVIDYGTCVCC 
Rattus norvegicus (Rat):  
      WICDKQCLCSAQNVIDYGTCVCC 
Homo sapiens (Human):      
     WICDKQCLCSAQNVIDYGTCVCC 
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The SRC Homology 3 (SH3) domain. 
 
Downstream of the CRD on SPRY2 on the C-terminal end is a proline-rich PXXPXR 
motif (termed the SH3 binding domain).  Lao et al., (2006) suggested that the SH3 
domain is exclusively responsible for silencing ERK phosphorylation through 
interaction of N-terminal GRB2 with the C-terminal SH3 domain of SPRY, which is 
achieved through preferential binding of PP2A over cCBL to the Y55 domain of SPRY2 
(Lao et al., 2007).  This indicates that exposure of the SH3 motif is required for SPRY2 
to naturally function as an antagonist of growth factor signalling.  However, other 
target proteins for the SH3 motif remain unidentified and their potential role in 
influencing SPRY2 function thus remains ambiguious.  
Properties of human bronchial epithelial cells and their use as a model 
of the fetal lung. 
SPRY2 expression has been poorly characterised in HBE.  However, this study sheds 
some new light on its expression in HBE as shown in Chapter 3, Figure 3.3, which  
illustrated that SPRY2 is expressed in the HBE cell line despite its expression being 
much weaker relative levels expressed in the FDLE cells.  The HBE cell line 
(16HBE14o-) used in this chapter were originally derived from immortalised 
bronchial surface epithelial cells from a 1-year-old transplant patient (Cozens et al., 
1994) and were established in culture through transfection of a pSVori plasmid.  
Under culture conditions, the HBE cell line was found to retain morphological and 
functional features of the lung epithelium.  For example, neighbouring cells develop 
tight junctions with one another to form a polarised ion transporting epithelial 
monolayer.  Cl- transport across this epithelium occurs through the Cystic Fibrosis 
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Transmembrane Conductance Regulator (CFTR), which critically maintains fluid 
homeostasis in the postnatal lung (Larson et al., 2000).  Interestingly, the HBE cell 
line exhibits high levels of CTFR protein and gene expression (Cozens et al., 1994), 
are capable of responding to FGF10 stimulation (Scott et al., 2010) and as shown in 
chapter 3, express SPRY2 albeit at approximately half the level of expression 
observed in FDLE (Figure 3.3).  This evidence, coupled with the conserved 
morphological characteristics and functional ion transport gradients, provide the 
potential for the HBE cell line as a sutiable candidate to study aspects of fetal lung 
development.   
The effect of modifying SPRY2 function on fetal lung development. 
 
The common theme that stems from the literature with respect to modfications 
made to each of the protein domains on SPRY2 described above, is that they all 
influence SPRY2’s function as an antagoniser of growth factor signalling and 
specifically as an inhibitor of ERK signalling, which is required for inducing growth of 
the airway in the fetal lung.  However, little or nothing his known as to how similar 
adaptations to SPRY2 effect vascular growth of the fetal lung.  Therefore, this 
chapter aims to examine the effects of modifying SPRY2 function on vascular 
signalling in response to SPRY2 overexpression and mutation of the functional Y55 
residue, the CRD and the SH3-binding motif.  The final part of this results chapter will 
examine the effects of SPRY2 knockdown by stable shRNA on HIF-1α transcriptional 
activity, kinase signalling and the gene expression of HIF-1α target genes including 
VEGF-A.  In order to manipulate SPRY2 function in vitro, the HBE cell line was 
selected as a representative of the fetal lung in culture 
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Results 
 
Overexpression of SPRY2WT abolishes and SPRY2Y55F induces HIF-1α 
promoter activity. 
For vascular development to occur, HIF-1α activity must be induced.  Therefore, HIF-
1α activity was examined in HBE in response to overexpression of SPRY2WT and 
constructs containing a null mutation in the Y55 tyrosine kinase phosphorylation 
domain (Y55F; SPRY2Y55F) or the SH3 protein binding domain (P304A, P307A, P308A), 
where the proline residues have been subsituted for phenylalanines.  Figure 4.2A 
shows the effects of transfecting these vectors in HBE has on HIF-1α activity.  
SPRY2WT abolished HIF-1α activity with increasing overexpression with a signficant 
difference in activity observed at a concentration of 2.5µgDNA.well-1 relative to 
untransfected cells.  HIF-1α activity did not change significantly with overexpression 
of SPRY2P304A-P307A-P308A.  However, HIF-1α activity was induced upon overxpression of 
SPRY2Y55F and this induction was also statistically significant at 2.5µgDNA.well-1.  
Figure 4.2B shows confirmation by western blot analysis of the overexpression of 
SPRY2 protein in HBE, upon transfection of all three vectors. 
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Figure 4.2.  Overexpression of SPRY2WT and Y55F/SH3 mutants and their effect on 
HIF-1α activtiy.  All experiments were performed at fetal pO2.  A. Activity of HIF-1α is 
measured as the HIF-luc luminescent response divided by that of pRL.   Values 
plotted are expressed as the fold change value relative to the endogenous response 
(SPRY2 0µgDNA.well-1).  Error bars are x  ± SEM of the fold change; n = 6.  Statistical 
analysis was carried out on the raw data where asterisks denote statistical 
significance (SPRY2WT; P < 0.05; SPRY2Y55F = 0.05; student’s t-test)  relative to the 
corresponding endogenous response (0µgDNA.well-1).  B.  Blots are representative of 
3 independent experiments.  Actin was blotted as a control for protein loading and is 
representative of the overexpression of all three SPRY2 western blots shown here. 
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Overexpression of SPRY2Y55F/P304A-P307A-P308A does not alter MAPK, PI3K 
and mTORC1 signalling. 
The result shown in Figure 4.2 established that HIF-1α activity was induced above 
the level evoked by hypoxia alone by overexpression of the SPRY2Y55F mutant, 
whereas the SH3 mutant tended to abrogate the inhibitory effect of SPRY2WT.  HIF-
1α activity is known to be regulated by ERK1/2, AKT and P70-S6K (Minet et al., 2000; 
Leung et al., 2011) and so the enodgenous activity of these kinases was assessed 
upon transfection of the SPRY2WT vector and the Y55F and SH3 mutants, as seen in 
Figure 4.3.  2.5µgDNA.well-1  of each of the SPRY2 vectors was transiently transfected 
into HBE and the phosphorylation pattern of P70-S6K, AKT and ERK1/2 was assessed.  
When compared to the endogenous HBE response, mutation of the Y55 and SH3 
domains of SPRY2 showed no significant change in the expression levels of of P70-
S6K, AKT and ERK1/2.   
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Figure 4.3.  Relative protein kinase abundance upon overexpression ± mutation of 
SPRY2.  Blots and densitometry are representative of 3 independent experiments.  A. 
P70-S6K phosphorylation measured at the Thr389 residue.  B. AKT phosphorylation 
measured at the threonine 308 (Thr308) residue.  C. p44/p42 (ERK1/2) 
phosphorylation measured at theronine 202 (Thr202) and tyrosine 204 (Tyr204) 
resdiues respectively.  Densitometric analysis of P70-S6K (D), AKT (E) and ERK1/2 (F) 
relative protein abundance is shown where bars represent the ratio of 
phosphorylated protein abundacne over total protein abundance.  Error bars are x  ± 
SEM (n = 3). 
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Mutation of the CRD of SPRY2 abolishes HIF-1α activity. 
WT-SPRY2 was subcloned from the pXJ40 vector into a  pCMV-Dual vector to 
generate N-terminal FLAG and C-terminal MYC tagged SPRY2.  Cysteines at postions 
218 and 221 of the putative ZnF domain were mutated to alanines and each 
construct was then used to generate stably transformed HBE cell lines.  The effects 
of HIF-1α activity in response to the expression of these three constructs (Figure 4.4) 
were examined in each cell line.  HIF activity was significantly suppressed in each cell 
line relative to the untransformed cells and the magnitude of this effect was greatest 
for the C218A mutant (P = 0.03). 
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Figure 4.4.  HIF-1α activity  of the stable HBE-SPRY2 cell lines measured by 
luciferase reporter gene assay.  Cells were maintained at 3% pO2.  HIF-1α  activity is 
measured as the HIF–luc luminescent response over that of pRL.  Values presented 
here represent fold change over the HBE WT response.  Error bars are representative 
of this fold change and are x  ± SEM; n = 4.  Asterisks denote statistical significance (P 
< 0.05) when compared to the WT response and statistical analysis was carried out 
on the raw data (student’s t-test). 
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HIF-1α protein stability and H3 phospho-acetylation are unaltered by 
SPRY2 overexpression and cysteine mutation. 
In chapter 3, a potential role for SPRY2 in regulating VEGF-A gene expression was 
established.  This potential was characterised by the observation that the loss of 
nSPRY239kDa correlated with an increase in phospho-acetylation of H3.  To link this to 
vascular signalling , the protein stability of HIF-1α was examined in order to assess 
whether the changes observed in Figure 4.4. occurred as a result of cleavage and 
clearence of HIF-1α from the nucleus.  Additionally, H3 phospho-acetylation was 
examined in these same cells to asses if the CRD of SPRY2 had an influence on 
histone modifications.  Figure 4.5. shows protein abundance of HIF-1α, SPRY2 and 
S10 phosphorylation/K14 acetylation of H3 in each of the SPRY2 HBE cell lines.  HIF-
1α nuclear protein abundance did not change upon overexpression of DT-SPRY2WT or 
both cysteine mutants (Figure 4.5A).  nSPRY2 protein was present in all SPRY2 stable 
cell lines and was statistically significant relative to the amount of nSPRY2 protein in 
untransformed HBE cells (Figure 4.5B).  However, there were no differences 
observed in H3 phospho-acetylation between each cell line. 
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Figure 4.5.  Nuclear HIF-1α and SPRY2 protein abundance and H3 phospho-
acetylation in response to C218A and C221A mutation.  Blots and densitometry are 
representative of 5 independent experiments.  A.  Total H3 was blotted as a control 
for protein loading  and for validation of nuclear protein extraction.  B.  
Denstiometric analysis of nSPRY2 protein abundance relative to H3 protein 
abundance.  Error bars are x    SEM of the raw data (n = 5).  Asterisks indicate 
statistical significance relative to the WT response (DT-SPRY2WT; P < 0.01; DT-
SPRY2C218A and DT-SPRY2C221A; P < 0.05; student’s t-test). 
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SPRY2 interaction with HIF-1α is abolished upon cysteine mutation. 
 
In chapter 3, a weak interaction was observed between SPRY2 and the HRE of the rat 
VEGF-A promoter, while a strong association was established between SPRY2 and 
CBP/p300 binding at the GC-rich sites downstream on the promoter (Figure 3.10).  
This suggests that an interaction may exist between SPRY2 and the HIF-1α-CBP/p300 
complex.  To investigate this further, an IP was carried out in order to establish if an 
interaction existed between these proteins.  In light of the observation that cysteine 
mutation suppressed HIF-1α transcriptional acitvity (Figure 4.4), it was hypothesised 
that cysteine mutation would suppress the putative interaction between SPRY2 and 
the HIF-1α-CBP/p300 complex.  Figure 4.6 shows the outcome of a Co-IP whereby 
SPRY2 antibody was used to ‘pull-down’ both HIF-1α and CBP/p300 protein.  The 
western blot shows that SPRY2 interacts with HIF-1α in both WT HBE and 
overexpressed DT-SPRY2WT cell lines and this interaction is attenuated upon C218 
and C221 mutation.  Attempts at pulling down CBP/p300 with SPRY2 proved 
unsuccessful (data not shown). 
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Figure 4.6.  Co-IP showing SPRY2 interaction with HIF-1α is lost upon mutation of 
C218 and C221.  Cells lysates were incubated with protein-A-sepharose beads 
conjugated with 1µg SPRY2 antibody and were probed for HIF-1α upon western 
blotting.  Blot shown here is representative of 3 independent experiments.  The band 
highlighted within the red box is HIF-1α protein. TCL denotes total cell lysate. 
 
Mutation of SPRY2 at Cysteine 218 induces VEGF-A gene expression. 
To further investigate the loss of HIF-1α  activity upon cysteine mutation of SPRY2, 
qPCR assays were performed to examine if this loss of HIF activity correlated with a 
change in the expression of the primary HIF-1α target gene, VEGF-A.  Figure 4.7. 
shows VEGF-A gene expression levels from each of the stable SPRY2 cell lines.  Little 
or no change was observed between the HBE WT and DT-SPRY2WT overexpression.  A 
strong induction of VEGF-A gene expression was observed in the DT-SPRY2C218A 
mutant relative to WT levels, which was found to be statistically significant (P < 
0.05).  However, DT-SPRY2C221A did not induce VEGF-A gene expression.  
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Figure 4.7.  VEGF-A gene expression levels in response to overexpression of 
SPRY2WT SPRY2C218A and SPRY2C221A.  A. VEGF-A mRNA levels were measured over 
B2M mRNA levels and graph bars represent fold change over the DT-SPRY2WT 
response.  Error bars are x  ± SEM of fold change (n = 4).  Asterisks indicate statistical 
significance relative to HBE WT (P < 0.05) where statistical analysis was carried out 
on the raw data.  B.  Representative melt curves for both the VEGF-A and B2M 
demonstrate the fidelity of the qPCR reaction.  Mean R² and efficiencies over 4 
independent assays are provided. 
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Mutation of SPRY2 at C218 and C221 abolishes the ability of SPRY2 to 
bind to the HRE of the VEGF-A promoter. 
Figure 4.6 established that SPRY2 interacts with HIF-1α, while Figure 3.10 also 
showed that SPRY2 binds to several DNA-binding domains of the VEGF-A promoter, 
where a weak interaction was observed at the HRE site.  To link these observations 
with the loss of HIF-1α activity induced by cysteine mutation of SPRY2, ChIP assays 
were performed to assess if mutation at C218 and C221 had any effect on the affinity 
of SPRY2 to bind to this region of the VEGF-A promoter (Figure 4.8).  SPRY2 was 
shown to bind strongly to the HRE upon overexpression (DT-SPRY2WT) and this effect 
was attenuated with C218 mutation and abolished upon C221 mutation.   The 
fidelity of this interaction was confirmed through the use of C-myc antibody in the 
ChIP assay (Figure 4.8B), as each of the DT-SPRY2 vectors harbour a C-terminal myc 
tag (Figure 4.7C). 
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Figure 4.8.  ChIP assays showing the effect of C218 and C221 mutation upon SPRY2 
binding to the HRE of the VEGF-A promoter (A).  Independent confirmation of this 
interaction is provided by the C-myc ChIP assay (B) as myc is fused to C-terminal 
SPRY2 in all three constructs (C).  HBE cells were transiently transfected with 
4µgDNA.well of each construct, where the empty vector transfected in was pCMV.  
H3 ChIP and the Input DNA were run as positive controls for the assay and the IgG 
ChIP was run as a negative control. qPCR reactions were run on 1% agarose gel and 
were stained with ethidium bromide.  Molecular weight of bands observed is 197bp. 
Results are representative of 2 independent experiments. 
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Stable transfection of SPRY2 shRNA in HBE silences SPRY2 protein and 
gene expression. 
 
To determine the effects of SPRY2 knockdown on HIF-1α activity and VEGF-A 
expression, HBE cells were stably transformed with either non-target (NT) or SPRY2 
shRNA.  Figure 4.9 shows confirmation of SPRY2 knockdown at the protein level in 
both cytosolic and nuclear fractions.  Protein abundance of SPRY2 was found to be 
significantly lower in the SPRY2 shRNA HBE line, irrespective of pO2.  Further 
confirmation of SPRY2 knockdown is provided in Figure 4.10 where SPRY2 mRNA is 
significantly reduced in the SPRY2 shRNA stable cell line at both fetal and normoxic 
pO2 where the extent of knockdown is approximately 60-70%. 
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Figure 4.9.  Western blot analysis confirming knockdown of SPRY2 protein with 
SPRY2 shRNA in HBE.  Blots and densitometry are representative of 3 independent 
experiments where error bars are x  ± SEM.  A.  Upper panel: Cytosolic SPRY2 protein 
abundance.  Lower panel: Nuclear SPRY2 protein abundance.  In either case, ß-Actin 
and P84 nuclear matrix proteins served as respective loading controls.  B. 
Densitometric analysis of the cytosolic and nuclear expression of SPRY2 was 
measured over ß-Actin and P84 respectively.  Asterisks denote statistical significance 
(P < 0.05; n = 3) relative to the response observed in the control shRNA at the 
respective pO2.   
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Figure 4.10.  SPRY2:B2M mRNA in the control and SPRY2 shRNA HBE cell lines in 
response to both fetal and normoxic pO2.  A.  SPRY2 mRNA was measured over B2M 
mRNA where the bars represent fold change in gene expression relative to the 
control shRNA at 3% pO2.  Error bars are x  ± SEM of fold change (n = 4).  Asterisks 
indicate statistical significance between SPRY2 and control shRNA at the respective 
pO2.  Statistical analysis was carried out on the raw data (* P < 0.05; ** P < 0.01; 
student’s t-test).  B.  Melt curve representatives for both SPRY2 and B2M genes, 
provided with average efficiency and R2 values (n = 4).  
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Knockdown of SPRY2 induces signalling of MAPK and mTORC1 in HBE. 
Figures 4.2 demonstrated that mutation of the functional domains of SPRY2 
significantly altered HIF-1α transcriptional activity and that this occurred without any 
significant change in kinase activity.  This result was surprising given the central 
position occupied by SPRY2 in growth factor signalling responses and thus the effect 
of SPRY2 knockdown was investigated on these pathways in response to FGF10 
stimulation.  Figure 4.11 shows protein abundance levels of mTORC1 as measured by 
P70-S6K phosphorylation at Thr389, in response to FGF10 stimulation in both control 
(Figure 4.11A) and SPRY2 shRNA (Figure 4.11B) HBE cell lines.  In NT shRNA, the ratio 
of phosphorylation at Thr389 to total P70-S6K expression appeared to increase with 
increasing FGF10 stimulation whereas a decline in the expression of P70-S6K 
phosphorylation was observed with SPRY2 shRNA (Figure 4.11A, B, D).  However, at 
endogenous levels, there was greater P70-S6K activity observed with SPRY2 shRNA 
relative to the control and this observation trended towards significance (Figure 
4.11C). 
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Figure 4.11.  Phospho P70-S6KThr389: Total P70-S6K relative protein abundance in NT 
and SPRY2 shRNA HBE cell lines in response to increasing FGF10 concentration.  
Cells were cultured at fetal pO2 and treated with FGF10 prior to whole cell lysis and 
subsequent western blot analysis.  Actin was blotted as a loading control.  Blots and 
densitometry are representative of 3 independent experiments where error bars are 
x  ± SEM.  A.  P70-S6K
Thr389 / Total P70-S6K in control shRNA.  B. P70-S6KThr389 / Total 
P70-S6K in SPRY2 shRNA.  C.  Densitometric analysis of endogenous P70-S6K activity 
in both shRNA cell lines where the induction in P70-S6K activity observed with SPRY2 
shRNA trended towards significance (P = 0.0576; student’s t-test).  D.  Densitometric 
analysis of P70-S6K activity in both shRNAs in response to increasing FGF10 
concentration. 
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The effect of SPRY2 shRNA and FGF10 stimulation on PI3K activity, as measured by 
AKT Thr308 phosphorylation, is shown in Figure 4.12.  Changes in AKT 
phosphorylation in response to FGF10 are associated with changes in the abundance 
of AKT protein and the direction of this response varied in magnitude from one assay 
to the next.  As a result, the compiled data showed no significant effect of either 
FGF10 or SPRY2 knockdown on PI3K activity. 
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Figure 4.12.  Phospho AKTThr308: Total AKT relative protein abundance in NT and 
SPRY2 shRNA HBE cell lines in response to increasing FGF10 concentration.  Blots 
and densitometry are representative of 3 independent experiments where error bars 
are x  ± SEM.  A.  AKT
Thr308 / Total AKT in control shRNA.  B.  AKTThr308 / Total AKT in 
SPRY2 shRNA.  C.  Densitometric analysis of endogenous AKT activity in both shRNA 
cell lines.  D.  Densitometric analysis of AKT activity in both shRNAs in response to 
increasing FGF10 concentration. 
 
 
 
 
109 
 
 
 
Figure 4.13 shows the effect of SPRY shRNA coupled with increasing FGF10 
stimulation on the protein abundance of ERK1/2.  ERK1/2 protein expression was 
measured at the p44 (Thr202) and p42 phosphorylation residues (Tyr204) in both NT 
and SPRY2 shRNA HBE cell lines (Figure 4.13A, B).  Without FGF10 stimulation, ERK1 
(p44) and ERK2 (p42) activity is induced upon SPRY2 knockdown by shRNA, relative 
to the NT shRNA (Figure 4.13C).  Upon FGF10 stimulation, ERK1 and 2 activities 
increased in the NT shRNA with increasing FGF10 concentration.  However, in the 
SPRY2 shRNA, ERK1 and 2 activities appear to increase specifically at 0.1µg.ml-1 
FGF10 before returning to levels observed in the endogenous response (Figure 
4.13D, E). 
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Figure 4.13.  Phospho ERK1/2Thr202/Tyr204: Total ERK1/2 relative protein abundance 
in NT and SPRY2 shRNA HBE cell lines in response to increasing FGF10 
concentration.  Blots and densitometry are representative of 4 independent 
experiments where error bars are x  ± SEM.  A.  ERK1/2
Thr202/Tyr204 / Total ERK1/2 in 
control shRNA.  B. ERK1/2Thr202/Tyr204 / Total ERK1/2 in SPRY2 shRNA.  C.  
Densitometric analysis of endogenous ERK1/2 activity in both shRNA cell lines.  D.  
Densitometric analysis of ERK1 (p44) activity in both shRNAs in response to 
increasing FGF10 concentration.  E.  Densitometric analysis of ERK2 (p42) activity in 
both shRNAs in response to increasing FGF10 concentration. 
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SPRY2 knockdown induces activity of HIF-1α at normoxic pO2. 
In the lung vasculature, activation of mTORC1 is required to induce the vascular 
activity of HIF-1α.  SPRY2 knockdown gave rise to mTORC1 and ERK1/2 activity as 
shown in figures 4.11 and 4.13.  Previous results from Scott et al., (2010), 
demonstrated that mTORC1 signalling induced HIF-1α activity.  Therefore, the effect 
of SPRY2 knockdown on HIF transcriptional activity was measured and VEGF-A 
expression at fetal and normoxic pO2.  Figure 4.14 shows cytosolic and nuclear HIF-
1α protein abundance in both NT and SPRY2 shRNA cell lines.  In the cytosol, HIF-1α 
abundance was suppressed in hypoxia upon SPRY2 shRNA.  However, upon 
incubation at normoxia, HIF-1α protein abundance was induced upon SPRY2 shRNA 
and this induction trended towards significance (P = 0.07; student’s t-test).  
Additionally, nuclear HIF-1α protein abundance is also induced upon SPRY2 
knockdown, where a marked change was observed in hypoxia, which also trended 
towards significance (P = 0.06; student’s t-test).  Only a relatively small induction of 
nuclear HIF-1α protein abundance was observed in normoxia. 
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Figure 4.14.  HIF-1α cytosolic and nuclear protein abundance in NT and SPRY2 
shRNA stable cell lines.  Cells were cultured in separate evenly seeded 6-well dishes 
for approximately 18 hours at both at both fetal and normoxic pO2 prior to lysis and 
fractionation.  Blots and densitometry shown represent 3 independent experiments 
where error bars are x  ± SEM of fold change.  A.  Cytosolic HIF-1α protein abundance 
with ß-Actin blotted as a control for protein loading.  B.  Densitometric analysis of 
cytosolic HIF-1α protein.  C.  Nuclear HIF-1α protein abundance. P84 nuclear matrix 
was run as a control for protein loading and validation of successful nuclear protein 
extraction.  D.  Densitometric analysis of nuclear HIF-1α protein. 
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Following on from the observation in Figure 4.14, the effect of SPRY2 knockdown on 
HIF-1α transcriptional activity was examined.  Figure 4.15 shows endogenous HIF-1α 
activity in both NT and SPRY2 shRNA HBE cell lines at both fetal and normoxic pO2 
measured by luciferase reporter gene assay.  At fetal pO2, a small decrease in HIF-1α 
activity is observed with SPRY2 shRNA relative to the control response.  At normoxic 
pO2 there is a near 4-fold induction of HIF-1α activity with SPRY2 knockdown.  
However, this induction is not significant relative to its NT shRNA counterpart (P = 
0.09; student’s t-test). 
 
Figure 4.15.  HIF-1α activity measured by luciferase reporter gene assay.  Activity of 
HIF-1α is measured as the HIF-luc luminescent response divided by that of pRL.     
Values generated are expressed as fold change relative to the response observed in 
the control shRNA at 3% pO2.  Error bars are x  ± SEM of the fold change (n = 5). 
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Loss of SPRY2 amplifies VEGF-A gene expression and alters CCND1 and 
BNIP3 expression. 
The impact that SPRY2 knockdown has on HIF-1α led to further investigation as to 
whether SPRY2 influences expression of the primary gene product of HIF-1α, VEGF-
A.  Figure 4.16 shows the outcome of qPCR assays which show measurements of 
VEGF-A gene expression in both NT and SPRY2 shRNAs.  At both fetal and normoxic 
pO2, VEGF-A gene expression is induced in the SPRY2 shRNA relative to the response 
observed in its NT shRNA counterpart.  This induction was shown to be statistically 
significant at both fetal and normoxic pO2. 
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Figure 4.16.  qPCR assay of VEGF-A gene expression in both NT and SPRY2 shRNA 
HBE cell lines.  Graphs and melt curves are representative of 4 independent 
experiments.  A.  Values generated are VEGF-A mRNA measured over B2M mRNA 
and graph bars represent fold change relative to the NT 3% shRNA response.  Error 
bars are x  ± SEM of the fold change.  Asterisks in the SPRY2 shRNA denote statistical 
significance relative to the NT shRNA response at the corresponding pO2 and 
statistical analysis was carried out on the raw data (P < 0.05; student’s t-test).  Melt 
curve representatives for VEGF-A (B) and B2M (C) are shown with their 
corresponding average efficiency and R2 values. 
 
 
 
 
116 
 
 
 
Having observed a significant role for SPRY2 in regulating VEGF-A gene expression, 
the influence of SPRY2 knockdown on the expression of other HIF target genes was 
investigated.  The HIF target genes examined in this study were Cyclin D1 (CCND1) 
and BCL2/adenovirus E1B 19kDa Interacting Protein 3 (BNIP3).  Figure 4.17 shows 
the effect that SPRY2 knockdown has upon CCND1 (4.16A) and BNIP3 (4.17B) gene 
expression at both fetal and normoxic pO2.  Regardless of pO2, a strong suppression 
of CCND1 gene expression is observed in SPRY2 shRNA relative to the NT shRNA 
response.  This effect is also observed with BNIP3 gene expression but only at 
normoxic pO2, whereas BNIP3 expression is actually amplified with SPRY2 shRNA at 
fetal pO2.   Taking oxygen into account, CCND1 gene expression was found to be 
greater at normoxia relative to hypoxia and this trended towards significance in NT 
shRNA HBE (P = 0.06; student’s t-test), while interestingly, HBE cells harbouring 
SPRY2 shRNA show a significant induction of BNIP3  gene expression in hypoxia 
relative to the normoxic response.  
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Figure 4.17.  qPCR assay of CCND1 and BNIP3 gene expression in both control and                                                                                                                                                                                                                                                                                                   
SPRY2 shRNA HBE cell lines.  Graphs and melt curves are representative of 4 
independent experiments. Values generated are CCND1 (A) / BNIP3 (B) mRNA 
measured over B2M mRNA and graph bars represent fold change relative to the 
control 3% shRNA response.  Error bars are x  ±SEM of the fold change.   Asterisks in 
the SPRY2 shRNA denote statistical significance relative to the NT shRNA response at 
the corresponding pO2 (* P < 0.05; ** P < 0.01; student’s t-test).  Hashtags denote 
statistical significance between SPRY2 shRNA at both O2 (## P < 0.01; student’s t-
test).  Melt curve representatives for CCND1 (C), BNIP3 (D) and B2M (E) are shown 
with their corresponding average efficiency and R2 values. 
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At normoxia, knockdown of SPRY2 shRNA promotes binding of the HIF-
1α-CBP/p300 scaffold to the HIF response element on the hVEGF-A 
promoter. 
To link the observations of SPRY2 shRNA-induced VEGF-A gene expression to that of 
HIF-1α activation, ChIP assays were performed to investigate if knockdown of SPRY2 
influenced binding of HIF-1α to the VEGF-A promoter.  Figure 4.18 shows the effect 
that knockdown of SPRY2 by shRNA has on the affinities of HIF-1α and its 
transcriptional co-activator CBP/p300 to bind to the HRE on the hVEGF-A promoter.  
At hypoxia, binding of the HIF-1α-CBP/p300 complex to the VEGF-A appeared to be 
unaltered by SPRY2 shRNA.  However, at normoxia, a strong signal for both HIF-1α 
and CBP/p300 is observed in the SPRY2 shRNA cell line relative to the NT shRNA 
signal. 
 
Figure 4.18.  ChIP assay showing the interaction of HIF-1α and CBP/p300 with the 
HRE of the hVEGF-A promoter in both NT and SPRY2 shRNA HBE cells.  IgG and H3 
chipped DNA were run as negative and positive controls respectively in the qPCR 
reaction.  qPCR reactions were run on 1% agarose gel and were stained with 
ethidium bromide.  Molecular weight of bands observed is 197bp. Results shown are 
representative of 3 independent experiments.   
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Discussion 
 
Prior to this study, SPRY2 function in the fetal lung had primarily been described in 
relation to airway growth, where it acts to antagonise the MAPK pathway through 
silencing of GRB2 (Casci et al., 1999; Tefft et al., 2002).  However, the data presented 
in Figure 4.2 suggests a potential role for SPRY2 in directing vascular growth through 
regulation of HIF-1α activity.  Figure 4.19 shows the anticipated configurations of 
SPRY2 in response to Y55 and SH3 domain mutation. 
 
 
Figure 4.19.  Schematic representation of SPRY2 protein structure upon 
overexpression (A), mutation of the SH3 domain (B) and mutation of the Y55 
domain.  A.  SPRY2 activity is induced upon c-Src phosphorylation of the Y55 domain, 
which promotes putative interaction of proteins with the SH3 domain.  B.  While 
SPRY2 activity is induced, the potential for the SH3 domain to bind other proteins is 
lost upon mutation of this domain.  C.  Upon null mutation of the Y55 domain, it is 
assumed that the SPRY2 remains ‘inactive’, as c-Src cannot phosphorylate the Y55 
domain. 
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Upon overexpression of SPRY2 (Figure 4.18A), it is assumed that Src-phosphorylation 
of Y55 occurs, which in turn promotes PP2A-induced dephosphorylation of the 
serine-rich domain.  This consequently allows the SH3 domain to become exposed, 
whose proline-rich ‘anchor’ could potentially bind interacting partners of HIF-1α and 
present them to cCBL for subsequent degradation.  Upon mutation of the SH3 
binding domain of SPRY2 (Figure 4.18B), HIF-1α activity was initially induced at low 
levels of transient overexpression but this activity tended to decrease upon 
increased overexpression of the mutant.  Under these circumstances, it is perceived 
that the potential for SPRY2 to sequester proteins for cCBL-targeted degradation is 
abolished, which would indicate that the SH3 domain specifically is not involved in 
regulating HIF-1α activity.  Conversely, HIF-1α activity progressively increased upon 
transient overexpression of the Y55 mutant.  This observation concurs with data 
published from our lab previously (Scott et al., 2010), where SPRY2Y55F also produced 
a rise in HIF-1α activity and VEGF-A secretion.  Under these circumstances, it is 
assumed that upon Y55 mutation, c-Src cannot phosphorylate Y55, the SH3 domain 
remains concealed and SPRY2 cannot interact with cCBL (Figure 4.18C).  This 
observation suggests that HIF-1α activity is linked to SPRY2 through phosphorylation 
of its Y55 residue, which in turn promotes interaction of SPRY2 with cCBL, resulting 
in sequestration and subsequent degradation of HIF-1α interacting proteins, 
contributing to the loss of HIF-1α activity in the epithelium.  One such interacting 
protein could be CBP/p300, which transcriptionally co-activates with HIF-1α in the 
nucleus (Land & Tee, 2007).  However, attempts at establishing an interaction 
between CBP/p300 and SPRY2 by Co-IP in this study proved unsuccessful. 
121 
 
 
 
Overexpression of SPRY2WT and the Y55/SH3 mutants did not alter P70-S6K, AKT and 
ERK1/2 phosphorylation relative to endogenous levels observed in WT HBE (Figure 
4.3).  This observation suggests that the changes in HIF activity induced by SPRY2 
protein modification are not mediated by differences in kinase activity. As such, 
these modifications may directly alter stability of the HIF-1α protein itself.  However, 
experiments have yet to be carried out in order to ascertain this.  Furthermore, it 
should be noted that overexpression of SPRY2WT produced a P70-S6K response near 
identical to that observed in WT HBE and surprisingly also showed an induction in 
the activity of AKT and ERK1/2 relative to the expression observed in WT HBE.  This 
observation may have been caused by the HBE cells becoming too saturated with the 
amount of SPRY2WT DNA transfected and as a result, the kinase activity observed 
may not be indicative of the true effect of overexpression and/or mutation of SPRY2 
protein.    
 
As discussed earlier in this chapter, the function of the CRD of SPRY2 is not well 
understood.  One school of thought suggests that it could act as a membrane 
targeting sequence and so disruption of this process by mutating C218 or C221 could 
increase the overall availability of SPRY2 to interact and repress HIF-1α activity.  It 
was hypothesised that this region is involved in DNA binding since the region 
spanning C218-C221 shares homology with the ZnF domain of RanBP2. 
Overexpression of the C218A and C221A mutants significantly repressed HIF-1α 
transcriptional activity (Figure 4.4), which was correlated by the abolishment of 
SPRY2 interaction with HIF-1α (Figure 4.6) and with the HRE of the VEGF-A promoter 
(Figure 4.8).  This novel finding would suggest the CRD of SPRY2 is responsible for 
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regulating the degree at which SPRY2 interacts with the VEGF-A promoter and 
ensures the fidelity of HIF-driven VEGF-A expression.  However, this idea is 
complicated by the observation that HIF protein stability did not change upon DT-
SPRY2WT overexpression or CRD mutation (Figure 4.5) and that C218A mutation 
induced VEGF-A gene expression (Figure 4.7).  Taking into consideration the general 
consensus surrounding the function of the CRD of SPRY isoforms, where it is thought 
to facilitate membrane translocation of SPRY itself (Impagnatiello et al., 2001), it is 
possible that SPRY2 may interact with HIF-1α directly through binding at C218 and 
upon membrane translocation, HIF-1α activity could be silenced and thus down-
regulate expression of the VEGF-A gene.  However, this study does not take into 
account the ability of both cysteine mutants to induce membrane translocation of 
SPRY2 so this theory is speculative.  The next step in this study would have been to 
test if SPRY2 palmitoylation is influenced by mutation of both of these cysteine 
residues.  However, time and resources proved to be a limiting factor. 
 
A clearer picture of the role of SPRY2 in vascular signalling emerged using shRNA 
knockdown of SPRY2; this was consistently observed at the level of protein and gene 
expression (Figures 4.9 and 4.10) and thus subsequent experiments were conducted 
in confidence that SPRY2 was expressed at low levels in these cells.  At endogenous 
levels, mTORC1 activity as measured by P70-S6K phosphorylation at Thr389 increased 
in SPRY2 shRNA HBE (Figure 4.11) and this induction trended towards significance.  
Similarly, ERK1/2 phosphorylation was also induced in SPRY2 shRNA HBE (Figure 
4.13).  FGF10 dose-dependently induced mTORC1 and ERK1/2 activity in the NT 
shRNA cells.  The former observation accords with Scott et al., (2010), which showed 
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that FGF10 stimulated HIF-1α vasculogenic activity via SPRY2.  The ERK1/2 response 
observed is consistent with several reports that its activity in lung in vitro models is 
induced by FGF10 (Upadhyay et al., 2003; Ding et al., 2007).  However, other studies 
have reported that attenuated FGF10 stimulation can suppress ERK1/2 
phosphorylation (Mailleux et al., 2005; Scott et al., 2010).  The decline in FGF10-
induced P70-S6K and ERK1/2 phosphorylation observed in the data suggests that the 
absence of SPRY2 destabilises the proliferative signal of FGF10 to induce 
downstream signalling of ERK and mTORC1, which could pose complications for 
epithelial differentiation of the airway and the vasculature respectively.  
Furthermore, the data presented here also conflicts with the notion presented by 
Land (2011), who used evidence from Scott et al., (2010) to suggest that FGF10 
signalling favours mTOR activity over that of ERK1/2, implying that SPRY2 directs 
partitioning of the FGF10 signal down either pathway.  In that regard, the effect of 
SPRY2 shRNA coupled with FGF10 stimulation on PI3K activity was examined.  As the 
PI3K pathway is distinct from the MAPK signalling cascade, it was postulated 
whether SPRY2 directed signalling of FGF10 to mTORC1 down through the PI3K 
pathway.  AKT phosphorylation was low in SPRY2 shRNA HBE relative to NT shRNA 
levels and this was not recovered by FGF10 stimulation (Figure 4.12).  This 
observation is in agreement with a study by Lito et al., (2009), who demonstrated 
that AKT phosphorylation decreased with down-regulation of SPRY2 and 
subsequently postulated that SPRY2 prevents DNA-damage induced apoptosis 
through part-regulation of AKT.  This is further supplemented by evidence showing 
that SPRY2 overexpression results in induced AKT phosphorylation (de Alvaro et al., 
2005; Sutterlüty et al., 2007).  To account for the varying kinase response to FGF10 
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stimulation, more repeats of these experiments would be required.  However, time 
and resources proved to be a limiting factor.  In addition to this, both cell lines were 
seeded at different densities to account for the difference in growth rates between 
the two cell lines, with the aim of achieving similar levels of cell confluency.  This 
may also have played a role in the varied responses observed in kinase activity.  
However, the endogenous responses observed were consistent across all 
experiments. 
 
HIF-1α protein stability was unaffected by SPRY2 shRNA at both fetal and normoxic 
pO2 (Figure 4.14).  In hypoxia, endogenous HIF-1α activity was slightly lower with 
SPRY2 shRNA, supporting the view that SPRY2 may act to regulate HIF-1α activation 
rather than stability.  However, VEGF-A gene expression was significantly induced 
(Figure 4.16), which would suggest that the hypoxic expression of VEGF-A may be 
induced independently of SPRY2-mediated HIF activation or that SPRY2 might have 
another function in the nucleus.  Surprisingly, HIF-1α activity was vastly induced in 
SPRY2 shRNA HBE at normoxia (Figure 4.15) and subsequent analysis by qPCR 
showed that significant up-regulation of VEGF-A mRNA also occurred in the absence 
of SPRY2 at normoxia (Figure 4.16).  HIF-1α can potentially be activated in tumours 
under normoxic conditions through genetic alterations in the oxygen-signalling 
pathway (So, 2012).  For example, HIF-1α is stabilised in normoxia upon mutation of 
proline 564 and PHD activity is inhibited upon interaction with Tricarboxylic Acid 
(TCA) intermediates such as α-ketoglutarate, succinate (Fang et al., 2001) and 
fumarate (Isaacs et al., 2005) 
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Given that SPRY2 acts as tumour suppressor in many organs, including the lung, this 
novel observation suggests that SPRY2 may ensure activation of HIF-1α only occurs 
in hypoxia, as its loss correlates with amplified HIF-1α activity in normoxia.  This 
finding conveniently correlates with data from the ChIP assays, which show that in 
normoxia, HIF-1α and its transcriptional co-activator, CBP/p300, bind strongly to the 
HRE of the hVEGF-A promoter (Figure 4.18) upon shRNA silencing of SPRY2 in HBE.  
This would mean that VEGF-A secretion from the epithelium is amplified in the 
absence of SPRY2 under normoxic conditions, further implying that the oxygen 
sensing component of HIF-1α, the PHD domain, may be regulated by SPRY2.  This 
idea appears to be supported by the observation that SPRY2 favours interaction with 
PHD1-3 isoforms during normoxia (Anderson et al., 2011).  Chen et al., (2010) 
demonstrated that both gene and protein levels of SPRY2 were decreased in 
response to hypoxia and this in agreement with the protein and mRNA data 
presented in Figure 4.9 and 4.10 respectively.  This would suggest that SPRY2 has its 
greatest repressive effect at normoxia where it ensures that HIF-1α and its specific 
target gene, VEGF-A are both activated only in hypoxia. 
 
Besides VEGF-A, SPRY2 appears to also play a role in the regulation of other HIF 
regulated genes.  The data presented in Figure 4.17A shows that CCND1 gene 
expression was severely down-regulated in SPRY2 deprived HBE in both fetal and 
normoxic pO2.  CCND1 is an established target gene of HIF-2α (Raval et al., 2005), 
where it functions as a regulator of the G1/S phase of the cell cycle and is known to 
form a complex with Cyclin-dependent Kinases (CDK).  This complex induces 
phosphorylation of retinoblastoma protein (pRb) allowing its entry into the S phase 
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of the cell cycle (Vízkeleti et al., 2012).  Overexpression of CCND1 disrupts the Rb 
pathway and is commonly observed in lung carcinomas and Non-small-cell Lung 
Cancers (NSCLC) and this expression is consistent with the emergence of epithelial 
tumours in many tissues (Betticher et al., 1997).  Down-regulation of CCND1 has 
been shown to induce cell cycle arrest (Sun et al., 2008) and the data presented here 
appears to show that this correlates with silencing of SPRY2.  This would suggest that 
SPRY2 may mediate CCND1 function on the cell cycle but presently there is no 
evidence that establishes a role for SPRY2 in mediating cell cycle progression.  
However, given the role of SPRY2 as a tumour suppressor, it is surprising that CCND1 
gene expression is not up-regulated in the absence of SPRY2.  Regardless of SPRY2 
shRNA, CCND1 gene expression was found to be greater at normoxia relative to 
hypoxia and this trended towards significance in the NT shRNA response.  This 
finding, coupled with the SPRY2 shRNA-induced activity of HIF-1α activity in 
normoxia, suggests that hyper-activation and overexpression of HIF-1α and CCND1 
respectively, may promote tumour formation.  Furthermore, this finding is 
supplemented by the fact that CCND1 expression is enhanced upon silencing of VHL 
(Bindra et al., 2002), where the hydroxylation of the HIF subunits occurs and its 
subsequent degradation is inhibited.   
 
BNIP3 is a member of the Bcl-2 family of proteins and its expression is up-regulated 
in hypoxia (Regula et al., 2002).  Upon induction, BNIP3 localises to the mitochondria 
where it where it triggers apoptosis of myocytes, neurons and epithelial cells (Jurasz 
et al., 2011).  The consensus that BNIP3 expression is induced in response to hypoxia 
is supported by the data presented here, which shows that BNIP3 gene expression is 
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greater in hypoxia relative to normoxia regardless of SPRY2 knockdown (Figure 
4.17B).  However, the absence of SPRY2 further induced BNIP3 expression in 
hypoxia, whereas at normoxia, BNIP3 gene expression was significantly down-
regulated upon SPRY2 knockdown relative to the control response.  The loss of 
BNIP3 is consistent with the formation of tumours, where down-regulation of BNIP3 
leads to the failure of tumour cells to apoptose, which clinically results in decreased 
patient survival (Burton & Gibson, 2009).  Given the loss of BNIP3 is induced further 
by SPRY2 shRNA in normoxia; it would appear that SPRY2 may regulate BNIP3 
activation through direct regulation of HIF-1α, thereby suppressing the activity of 
both HIF-1α and its target gene, BNIP3, at normoxia.  However, this result is 
inconsistent with the hyper-activation of HIF-1α observed under these conditions as 
shown in Figure 4.15. 
Conclusions 
 
Based on the results presented in this chapter, it is possible that SPRY2 plays a role in 
regulating epithelial development of both the airway and the vasculature.  In 
hypoxia, SPRY2 acts to repress HIF-1α transcriptional activity.  Mutation of SPRY2 at 
the C-terminal SH3 domain relieves this repression, while mutation of SPRY2 at Y55 
promotes HIF-1α activity, independent of kinase activity.  This study sheds new light 
on the function of the CRD of SPRY2, whereby mutation of the CRD suppressed HIF-
1α activity and abolished SPRY2 interaction with HIF-1α and the VEGF-A promoter, 
which appears to support the hypothesis that the CRD of SPRY2 acts as a DNA 
binding domain.  The absence of SPRY2 in HBE induces ERK1/2 and mTORC1 activity 
and also the expression of hypoxia-regulated genes; VEGF-A and BNIP3, whilst at 
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same time, disrupting the FGF10/FGFR2b feedback loop.  This chapter also presents 
an additional potential nuclear role for SPRY2 whereby it may mediate cell cycle 
progression through regulation of CCND1.  Finally, the results also postulate that 
SPRY2 acts to repress the activation of HIF and its regulated gene products at 
normoxia.  The results of this and the previous chapter and their implications on the 
airway and vascular development of the fetal lung will be discussed further in the 
general discussion. 
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Chapter 5 - General Discussion 
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Introduction 
 
Prior to this study, the majority of research on SPRY2 in the developing lung 
epithelium has primarily focused on its role to antagonise signalling of the 
FGF10/FGFR2b axis, thereby suppressing the proliferative signal to ERK resulting in 
reduced airway branching morphogenesis.  However, little is known regarding the 
intimate coordination between growth of the airway and vascular trees and as such 
little is reported of the role of SPRY2 in regulating the molecular mechanisms that 
orchestrate this co-ordination.  This issue is addressed in this thesis, where the 
original aim was to establish a potential role for SPRY2 in co-ordinating both airway 
and vascular development of the epithelium.   
Overexpression of SPRY2 inhibits airway and vascular growth of the 
fetal lung. 
 
Overexpression of the SPRY isoforms has been consistently shown to inhibit growth-
factor-induced cell growth and proliferation (Edwin et al., 2006).  While much of the 
literature confines SPRY2 function to its role in inhibiting the growth-factor-
mediated MAPK signalling cascade, the results presented in this thesis show that 
overexpression of both SPRY2WT and DT-SPRY2WT constructs in HBE represses 
vascular development via HIF-1α transcriptional activity.  This observation suggests 
that SPRY2 is involved in negatively regulating HIF-1α activity, which is further 
supported by the evidence that knockdown of SPRY2 by shRNA had the opposite 
effect on HIF-1α activity. 
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Phosphorylation of SPRY2 at Y55 regulates basal HIF-1α activity. 
 
The earliest experiments examining SPRY2 function established that its activation 
was linked to tyrosine phosphorylation, with particular emphasis placed on 
phosphorylation of the Y55 residue (Sasaki et al., 2001; Fong et al., 2003).  
Subsequently, much of the research on SPRY2 function in vitro has focused on the 
manipulation this residue.  This led to the creation of the Y55F mutant, which 
functions by forming heterodimers with endogenous SPRY2 and interferes with 
binding of SPRY2 to its targets in the MAPK pathway (Wietecha et al., 2011).  
Sutterlüty et al., (2007) confirmed this in lung cells by showing that overexpression 
of SPRY2Y55F resulted in the failure of SPRY2 to inhibit ERK phosphorylation.  In this 
thesis, SPRY2Y55F overexpression significantly up-regulated endogenous HIF-1α 
activity and this observation occurred independently of FGF10 stimulation and 
kinase signalling activity.  This indicates that endogenous SPRY2 acts to antagonise 
HIF-1α activity as it does with MAPK signalling.  This is further supplemented by the 
observation that knockdown of SPRY2 by shRNA promoted both endogenous ERK1/2 
and mTORC1 phosphorylation, thus linking the inhibitory function of SPRY2 to both 
airway and vascular signalling cues. 
The SH3 domain of SPRY2:  a docking station for G-proteins? 
 
Further experimentation with modifying SPRY2 function led to the discovery of a 
proline-rich C-terminal domain; the PXXPXR motif, termed here the SH3-binding 
motif.  Lao et al., (2006) made a series of point mutations within the PXXPXR motif of 
SPRY2 and subsequently demonstrated a reduction in the ability of SPRY2 to bind to 
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GRB2 within the MAPK pathway.  This observation proved that the SH3 binding 
domain of GRB2 can bind to the proline-rich PXXPXR motif of SPRY2.  The results in 
this thesis surprisingly did not show an increase in ERK1/2 phosphorylation upon SH3 
mutation of SPRY2.  However, HIF-1α activity was induced, suggesting that the SH3 
domain may act in concert with the Y55 domain to repress HIF-1α activity.  Given 
that the SH3 motif of SPRY2 can interact with GRB2, a G-protein consisting of a SH3-
SH2-SH3 domain configuration, it is possible that this region of the SPRY2 protein can 
interact with other SH3-domain-containing proteins that are known to regulate 
mTORC1 expression, which is required for HIF-1α activation. Evidence to support this 
hypothesis is provided by Ying et al., (2010), who described that Ras-related C3 
Botulinum Toxin Substrate 1 (RAC1), a known regulator of mTORC1 (Saci et al., 
2011), is inhibited via SPRY2 interaction with the SH3 domain of ßPix; a membrane-
targeting Guanine Nucleotide Exchange Factor (GEF) protein required for RAC1 
activation.  Furthermore, a recent publication from Kim et al., (2012), demonstrated 
that SH3 Domain-binding Protein 4 (SH3BP4) binds to the Recombination Activating 
Genes (RAG) GTPase complex through its SH3 domain resulting in the failure of this 
complex to become activated, which leads to a suppression of mTORC1 activity.  The 
identification of SH3 binding sites on several GAP members such as RasGAP (Bos et 
al., 2007) and RAC1 provide further credence for their potential to interact with 
SPRY2.  Therefore, it is possible that SPRY2 may act as a docking station for SH3 
containing proteins, particularly G-proteins (considering GRB2 is a known binding 
partner).  The SH3 binding domain then presents these proteins to cCBL, which is 
bound to the Y55 domain of SPRY2, where it functions to degrade and silence the 
activity of proteins bound to the SH3 binding motif.   
133 
 
 
 
Regulation of basal vascular signalling by SPRY2 occurs independently 
of the PI3K/AKT signalling cascade. 
 
The results presented in this thesis show that endogenous AKT phosphorylation was 
unaffected upon modifications made to the SPRY2 protein.  This would suggest that 
SPRY2 antagonises mTORC1 activation independently of PI3K activity.  Several 
studies have indeed reported that S6K phosphorylation at Thr389 is PI3K-independent 
(Tamburini et al., 2009; Park et al., 2010). If this is the case, then something else 
must be driving the activation of mTORC1.  A possible candidate for this could be 
Rheb; where its overexpression has been reported to induce mTOR signalling 
independently of PI3K activation (Goodman et al., 2010).  This observation is 
reflected in data from Scott et al., (2010), who showed that mTORC1 activity was 
induced via S6K phosphorylation at Thr389 through co-expression of Rheb and HIF-1α 
in Human Epithelial Mesenchymal Lung Fibroblast Cells (HELMF).  However, it is 
unclear if Rheb interacts with SPRY2 as it is not known to possess a SH3-binding 
domain.  To complicate matters further, it has been established that amino acid-
induced activity of mTORC1 can occur independently of Rheb, by means of RAG-
GTPase catalysis (Kim et al., 2008).  
Silencing SPRY2 disrupts the FGF10/FGFR2b/SPRY2 feedback 
mechanism. 
 
The results in this thesis establish that knockdown of SPRY2 could pose implications 
on the co-ordinated development of the airway and the vasculature as both ERK1/2 
and mTORC1 activities are induced at endogenous levels.  The observation that AKT 
expression was repressed upon SPRY2 shRNA provides further evidence that 
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downstream regulation of mTORC1 by SPRY2 occurs independently of the PI3K/AKT 
signalling cascade.  As alluded to in the results, SPRY2 shRNA appeared to also 
destabilise the FGF10 proliferative signal that promotes protein-kinase activity, 
which provides further evidence that SPRY2 is a vital component of the negative 
feedback mechanism that governs FGF10 stimulation.  This suggests that disruption 
of the FGF10/FGFR2b/SPRY2 feedback mechanism could lead to unsustained 
proliferation of both airway and vascular signalling.  Thus, it would appear that this 
feedback mechanism is dependent upon SPRY2 acting as ‘molecular clock’ where it is 
responsible for regulating the duration of the FGF10 signal, which would imply that 
SPRY2 is responsible for directing the bifurcation of the developing airway.  This idea 
is discussed at length by Scott et al., (2010) who described the FGF10/FGFR2b/SPRY2 
relationship as an ‘airway branching periodicity regulator’ which also factors in HIF-
1α driven vasculogenesis.  However, it is possible that this mechanism may extend to 
the nucleus where SPRY2 potentially facilitates the unwinding of DNA from its 
histone core in a time-dependent facet.  It should be noted that FGF10 treatment on 
these cells was carried out at a dose-dependent rate so it may have been more 
informative to have carried out a time-course experiment to establish if SPRY2 
expression was altered in a time-dependent manner upon FGF10 stimulation.   
 
While this study is confined to examining the SPRY2-FGF10 feedback mechanism, 
SPRY2 activity is also linked in a feedback mechanism with other growth factor 
transmembrane complexes, such as the EGF receptor (EGFR).  In a similar 
mechanistic activity to FGFs, EGFR dimerisation induces signalling of both the MAPK 
and PI3K/AKT pathways promoting cell growth and migration respectively.  Their role 
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in lung development is to promote maturation of the ATII cells and the secretion of 
surfactant (Li et al., 2012).  However, unlike FGF10, overexpression of SPRY2 has 
been reported to enhance EGFR signalling preventing its interacting with cCBL (Kim 
& Bar-Sagi, 2004).  Therefore it may have been informative to also examine the 
effect of modifying SPRY2 function upon EGF signalling in the lung epithelium.   
SPRY2 regulates both airway and vascular signalling. 
 
Scott et al., (2010) reasoned that SPRY2Y55F permits Rheb-GTP driven activation of 
mTORC1 since the mutant is incapable of binding cCBL and direct targeted 
degradation of the TSC1/2 complex that is responsible for inhibiting mTORC1 
signalling activity.  However, the mechanism behind the interaction between SPRY2 
and TSC1/2 is unknown.  It is also unclear if there is a role for the SH3-binding motif 
of SPRY2 in regulating this process or if indeed the TSC1/2 complex interacts with 
this motif.  Therefore, this thesis predicts a new mechanism by which mTORC1 
activity is directly regulated by SPRY2, which deviates from that described by Scott et 
al., (2010) (Figure 5.1).  The SH3 domain of a GAP (e.g. RAC1, RAG GTPase) that is 
known to constitutively activate mTORC1, binds to the C-terminal PXXPXR motif on 
SPRY2 where it is targeted for degradation by cCBL.  This causes inhibition of 
mTORC1 activity resulting in the failure of HIF-1α to translocate to the nucleus and 
induce the expression of vascular genes.  Conversely, putative interaction of TSC1/2 
to the PXXPXR motif would promote uncoupling this complex allowing Rheb-GTP 
catalysis and the activation of mTORC1.  While this new model is comprised of 
evidence from the results in this thesis and that of the literature, there is no 
experimental basis to establish the ability of the PXXPXR motif of SPRY2 to 
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specifically interact with GAP proteins bearing SH3 binding domains.  It is also 
unknown if this motif selectively targets any SH3-domain-containing proteins or if 
indeed these proteins will compete with each other for binding to SPRY2.  In order to 
prove this, a Co-IP assay could be setup to see if GAP proteins interact with SPRY2 
and if any putative interaction is abolished by mutation of the PXXPXR motif of 
SPRY2.  
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Figure 5.1.  Model of SPRY2 regulating co-ordinated airway and vascular signalling 
of lung epithelium.  A.  FGF10 stimulates RTK signalling of the MAPK pathway at the 
cell membrane.  B.  FGF10 also stimulates activity of mTORC1 downstream, 
independently of PI3K/AKT activity.  C. c-Src binds to the Y55 domain of SPRY2 upon 
FGF10 stimulation and phosphorylates SPRY2 permitting exposure of the cryptic C-
terminal PXXPXR domain and the interaction of cCBL with SPRY2 at Y55.  D.  GRB2 is 
sequestered by the proline-rich PXXPXR motif of SPRY2 where it is subsequently 
degraded by cCBL (red dashed arrow).  The net effect is a disruption of the MAPK 
signalling cascade and a failure of ERK to signal growth of the airway towards the 
FGF10 stimulus. E. Vascular signalling is inhibited through the interaction between 
SPRY2 and the SH3 binding sites of GAP proteins at the PXXPXR motif.   These GAP 
proteins are subsequently silenced by cCBL interaction in a similar mechanism to 
that of GRB2 sequestration by SPRY2.  F. Putative interaction between the TSC1/2 
complex and the PXXPXR motif permits Rheb-GTPase driven mTORC1 activity as 
originally speculated by Scott et al., (2010). 
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Could SPRY2 regulate the oxygen-sensing component of HIF-1α? 
 
At normoxia, HIF-1α is targeted for destruction which occurs through O2-dependent 
hydroxylation of proline residue by pVHL E3 ubiquitin ligase (Maxwell et al., 1999; 
Bruick & McKnight, 2001).  Knowles et al., (2006) determined that a lack of 
hydroxylation of at least one of the prolyl residues was responsible for the 
expression of HIF-1α in normoxia.  However, this induction in HIF-1α expression was 
caused through application the potent tumour promoter drug, Phorbol 12-myristate 
13-acetate (PMA).  The alternative approach in this study was to silence the known 
tumour suppressor gene SPRY2, which resulted in a hyper-activation of HIF-1α 
expression in normoxia and was complemented by the enhanced interaction 
between HIF-1α and CBP/p300 to the VEGF-A promoter.  This suggests that SPRY2 
may act upon the oxygen sensing capabilities of HIF1α under normoxic conditions.  A 
possible explanation for this is that SPRY2 may interact with the pVHL E3 ubiquitin 
ligase in normoxia, upon which it permits pVHL to administer degradation of HIF-1α.  
Evidence to suggest this primarily stems from the fact that SPRY2 can interact with a 
number of other E3 ubiquitin ligases.  While the interaction between SPRY2 and cCBL 
is well-defined, another E3 ubiquitin ligase known to interact with SPRY2 is Seven-in-
Absentia Homolog 2 (SIAH2), where it acts to regulate SPRY2 protein stability and 
sustain MAPK activity independently of RTK-induced tyrosine phosphorylation of 
SPRY2 (Nadeau et al., 2007).  Additionally, SIAH2 is also responsible for regulating 
the stability of the PHD1 and PHD3 domains of HIF-1α in hypoxia, whilst ensuring 
that HIF-1α transcriptional activity is prevented at normoxia (Nakayama et al., 2004; 
Qi et al., 2008).  Given this dual function of SIAH2, it is possible that SPRY2 may act to 
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present SIAH2 with the PHD domains of HIF-1α, much like the mechanism whereby 
SPRY2 presents cCBL with its substrates in order to inhibit ERK and potentially 
mTORC1 activity.  Anderson et al., (2011), established through Co-IP that SPRY2 
preferentially interacts with pVHL in normoxia which provides further credence for a 
role for SPRY2 in regulating HIF-1α stability. Additionally, by mutating the proline 
residues on SPRY2, Anderson et al., (2011) showed that the interaction between 
SPRY2 and pVHL was severely diminished and SPRY2 protein had stabilised.  This 
confirmed a mechanism whereby SPRY2 too is hydroxylated by PHDs and is 
subsequently destroyed by pVHL E3 ubiquitin ligase.  This suggests that a potential 
feedback mechanism occurs between pVHL targeted degradation of HIF-1α and 
SPRY2. However, where exactly pVHL interacts with SPRY2 has not yet been 
established and it is also unclear if this process disrupts the potential for mTORC1 to 
interact with HIF-1α and induce its nuclear translocation.  Given that this thesis has 
examined the role of the proline-rich SH3 motif of SPRY2, it could be possible to 
assess if pVHL would fail to interact with SPRY2 upon mutation of its SH3 binding 
motif.  This would present an additional means whereby SPRY2 regulates HIF-1α 
activity, which is independent of mTORC1 activity but dependent on oxygen.  In 
order to link both SIAH2 and pVHL function upon HIF-1α with their ability to interact 
with SPRY2, a model is presented in Figure 5.2.  This model demonstrates a putative 
mechanism whereby SPRY2 presents either E3 ubiquitin ligase SIAH2 or pVHL with 
the PHD of HIF-1α, where it can direct degradation of this protein in normoxia. 
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Figure 5.2.  Model of SPRY2-mediated HIF-1α activity in hypoxia and normoxia.  A.  
In hypoxia, mTORC1 binds to a TOS motif within the first PAS domain (Land & Tee, 
2007) near the N-terminal bHLH domain.  Upon nuclear translocation, CBP/p300 
binds to the C-TAD of HIF-1α and induces transcriptional activity of VEGF-A.  B.  
SPRY2 presents the SIAH2 or pVHL E3 ubiquitin ligase to target degradation of the 
PHD on HIF-1α and silence its activation, thus preventing transcriptional activation of 
VEGF-A.  
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The role of the CRD of SPRY2: does it regulate VEGF-A expression in a 
HIF-dependent manner? 
 
The results presented in this thesis provide indication of a novel role for the CRD of 
SPRY2.  Mutation of C218 and C221 suppressed HIF-1α activity and this was 
accompanied by the failure of both of these mutants to bind to the HRE of the VEGF-
A promoter.  This suggests that the CRD of SPRY2 plays an important role in 
regulating the extent at which SPRY2 functions to repress HIF-driven VEGF-A 
expression.  In light of the ZnF binding homology with RanBP2, the putative ZnF 
domain of SPRY2 may be involved in recruiting HIF-1α away from the HRE of the 
VEGF-A promoter, thus preventing its transcriptional activation.  If this is the case, 
then HIF-1α must directly interact with SPRY2.  This is supported by the evidence in 
Figure 4.6, whereby SPRY2 was shown to interact with HIF-1α, which further 
suggests that a complex may exist between these two proteins.  Furthermore, the 
results from this experiment showed that cysteine mutation abolished this 
interaction, which further supports the hypothesis that the CRD of SPRY2 is 
responsible for directing HIF-1α driven transcriptional activation of VEGF-A. 
On the other hand, these hypotheses are complicated by the observation that HIF-1α 
protein abundance was unaltered across each cell line and mutation of C218A 
actually induced VEGF-A gene expression, which suggests that VEGF-A expression 
may occur via a HIF-independent mechanism.  The VEGF-A promoter is comprised of 
a number of different of DNA-binding sites, which bind transcription factors that are 
responsible for up-regulating VEGF-A gene expression, independently of HIF.  Two of 
these sites were examined on the hVEGF-A promoter in this study, the STAT3 and 
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GC-rich Sp1/3 transcription factor binding sites located further downstream.  
However, problems were encountered with the ChIP assay analysis in this study in 
trying to establish binding of SPRY2 and the mutants at these regions, so it is difficult 
to ascertain if SPRY2 may regulate VEGF-A in a HIF-independent manner. 
STATS are a group of transcription factors that become phosphorylated upon RTK 
and/or cytokine activity, resulting in their subsequent translocation to the nucleus 
where they bind to promoters of genes and regulate their transcriptional activity (Yu 
& Jove, 2004).  Interestingly, STAT phosphorylation can also be induced from the 
activity of non-RTKs such as Src kinase (Yu et al., 1995), which is also known to 
phosphorylate SPRY2. The STAT3 isoform has been shown to correlate with VEGF 
production in a variety of human cancers and previous ChIP assays by Niu et al., 
(2002), revealed that STAT3 binds to the VEGF promoter in vivo and thus directly 
regulates VEGF gene expression.  This was confirmed by the observation that 
mutation of the STAT3 binding domain abolished VEGF gene expression.  Further 
ChIP assays by Gray et al., (2005) showed that there is evidence to suggest that 
STAT3 and HIF-1α bind to the VEGF promoter simultaneously upon Src activity.  They 
also demonstrated by Co-IP that both HIF-1α and STAT3 interact with each other, 
which led to the conclusion that it is possible that HIF-1α and STAT3 could form a 
complex on the VEGF promoter as the HRE and STAT3 binding sites are in close 
proximity.  This observation draws interesting parallels with the results in this thesis 
as like STAT3, SPRY2 was shown to Co-IP with HIF-1α and bind to the VEGF-A 
promoter.  Therefore it is possible that like STAT3, SPRY2 could complex with HIF-1α 
on the VEGF-A promoter and direct transcriptional regulation of the VEGF-A gene.  
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The next step to establish this would be to demonstrate by Co-IP if SPRY2 also 
interacts with STAT3.   
Sp1 and its repressor Sp3 are also critical regulators of HIF-independent VEGF-A gene 
expression and function downstream near the transcriptional start site in GC-rich 
regions, which are highly susceptible to methylation.  Milanini-Mongiat et al., (2002), 
showed that phosphorylation of Sp1 upon ERK activation promotes VEGF expression 
and mutation of the serine and threonine residues of Sp1 subsequently abrogated 
VEGF expression. Furthermore, Sp1 up-regulation of VEGF transcriptional activity is 
thought to occur downstream of PI3K activity in a HIF-independent manner (Choi et 
al., 2011). The interaction between SPRY2 and these DNA-binding sites suggests that 
SPRY2 regulation of VEGF-A gene expression may occur via both HIF-independent 
(through GC-rich domain binding) and/or HIF-dependent mechanisms (via complex 
formation with HIF-1α and STAT3).   
Given the hypothesised role of the CRD in facilitating SPRY membrane localisation 
(Lim et al., 2000), an assay to measure protein palmitoylation such as that designed 
by Forrester et al., (2011), could’ve been conducted to assess whether mutation of 
SPRY2 at C218A/C221A affected the ability of SPRY2 to traffic to the cell membrane, 
as established by Impagnatiello et al., (2001).  Given that SPRY2 translocates to the 
plasma membrane in response to FGF10 (Lim et al., 2000) this would suggest that 
mutation of the CRD would lead to a disruption of the SPRY2 inhibitory action upon 
both the MAPK and mTORC1 signalling pathways. To link CRD function of SPRY2 to 
that of the Y55 and PXXPXR motif, it may have been intuitive to conduct experiments 
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examining kinase activity which would’ve provided further insight if the CRD of 
SPRY2 affected both MAPK and mTORC1 signalling pathways. 
The nuclear role of SPRY2: an epigenetic regulator of gene expression? 
 
The major finding of this thesis was the novel discovery of SPRY2 protein in the 
nucleus in both cultured ex vivo FDLE and in vitro HBE.  While nuclear localisation of 
SPRY2 has been reported only in mouse embryonic fibroblasts (Ahn et al., 2010) and 
neuronal cells (Aranda et al., 2008), its function in the nucleus remains unknown.  
Given that the results show a correlation between the FGF10-induced loss of full-
length SPRY2 and the increase in H3 phospho-acetylation, a new role for FGF10 is 
described in this thesis whereby FGF10 induces unwinding of DNA from their histone 
core, which is catalysed by histone acetyltransferase activity, leading to increased 
gene expression.  This occurs in the absence of full-length SPRY2, whose expression 
correlates with that of HDAC1 and 2.  This would mean that SPRY2 could act to 
repress mitotic initiation and subsequent gene expression and this effect is relieved 
by dose-dependent FGF10 stimulation.   
 
As FGF10 is known to induce the signalling pathways that govern airway and vascular 
development, it is assumed that FGF10 would induce the major vascular gene 
product, VEGF-A and the results in this thesis show a trend for this to be the case.  
Furthermore, SPRY2 was shown to interact with the VEGF-A promoter, particularly at 
regions spanning CpG methylation sites.  As alluded to in the results, these CpG 
islands are in close proximity to the transcriptional start site and are susceptible to 
DNA methylation through interaction with methyl-CpG-binding proteins, which can 
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lead to gene silencing (Nan et al., 1997).  An example of such a protein is Methyl CpG 
Binding Protein 2 (MeCP2), which is expressed in lung tissue and has been shown to 
bind to and methylate CpG domains on the Peroxisome Proliferator-activated 
Receptor-gamma (PPAR-γ) promoter (Joss-Moore et al., 2011), a nuclear receptor 
that is expressed in airway epithelium and regulates both lung epithelial cell 
differentiation and gene expression (Wang et al., 2001).  Considering that both DNA 
methylation and histone deacetylation interplay to silence gene expression and that 
deacetylation appears to correlate with SPRY2 expression (as shown in Figure 3.6), it 
is possible that SPRY2 acts to antagonise transcriptional activation through either or 
both of these processes in order to regulate the interaction of transcription factors 
(such as Sp1/3) with the GC-rich domain.   
 
In order to collate these observations, a model is presented in Figure 5.3, postulating 
the mechanism behind FGF10-induced gene expression, which is antagonised by 
SPRY2 activity.  However, this model does not take into account if SPRY2 regulates 
airway growth in a similar manner.  A potential experiment to test this would to 
measure the expression of genes that are hallmarks of the MAPK pathway, such as 
Interleukin 1ß (IL-1ß), IL-6 and IL-8, which were shown to be sensitive to specific 
MAPK inhibitors (Hedges et al., 2000).   
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Figure 5.3.  Proposed model of vascular gene expression induced FGF10 evoked 
‘cleavage’ of SPRY2.  The loss of full-length SPRY2 permits FGF10-induced activation 
of mTORC1 which binds to the TOS motif on HIF-1α signalling its translocation to the 
nucleus.  In the nucleus, the histone acetyltransferase CBP/p300 binds to the C-TAD 
domain of HIF-1α and this complex binds to the HRE of the VEGF-A promoter.  
Simultaneously, CBP/p300 catalyses the phosphate and acetyl groups exposed on 
the Histone 3 tails, leading to unwinding of the VEGF-A DNA from its Histone core 
and thus increasing the potential for transcriptional activation and subsequent gene 
expression. Transcriptional activation is governed by SPRY2 interaction with the CpG 
island domain inducing methylation and silencing of the promoter thereby inhibiting 
VEGF-A gene expression.  
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The ideas presented in this thesis also suggest a more global role for SPRY2 as a key 
regulator of cell division.  Evidence to support this hypothesis is provided by Tang et 
al., (2011), who showed that the loss of SPRY2 function resulted in the abnormal 
mitotic arrangement of the spindle fibres, which led to abnormalities in airway shape 
and also conveniently correlated with increased ERK1/2 activity, albeit through the 
use of mathematical models.  The results presented in this thesis provide more 
insight into a potential role for SPRY2 in regulating mitotic cell cycle activity, where a 
loss of SPRY2 was shown to have an adverse effect on gene expression, particularly 
that of CCND1, whose expression was severely compromised upon SPRY2 
knockdown in HBE.  Complimenting this finding is a study by Mayer et al., (2010), 
who conducted northern blot experiments to show that SPRY2 RNA is expressed 
during the exit phase of the cell cycle.  This publication also demonstrated SPRY2 
expression declined in the G1/S boundary of the cell cycle, which they attribute to 
cCBL interaction.  However, this study fails to establish a potential function for SPRY2 
in regulating the cell cycle.  The results from this study appear to suggest that SPRY2 
may act to direct cell-cycle progression by regulating the expression of CCND1.  To 
further investigate this possibility, a microarray experiment could be used to identify 
if SPRY2 is indeed a regulator of the cell cycle, much like the one conducted by 
Whitfield et al., (2002), who isolated mitotic Human Cancer Cell Line Cells (HeLa) and 
manufactured cDNA microarrays to determine a library of cell-cycle regulated genes.  
However, the capacity to conduct such an experiment was unavailable. 
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SPRY2: the missing link that coordinates airway and vascular growth of 
the fetal lung. 
 
The results in this thesis have presented an argument that SPRY2 acts an antagonist 
of growth-factor induced airway and vascular growth, coupled with the novel 
observation that SPRY2 is present in the nucleus where it potentially acts to repress 
gene expression.  In order to link these two functions together and thus establish 
SPRY2 as a key regulator of co-ordinated lung airway and vascular development, a 
model has been constructed describing the mechanism behind co-ordinated airway 
and vascular growth of the fetal lung (Figure 5.4), which expands upon the 
integrated model of airway and vasculogenesis described by Scott et al., (2010).   
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Figure 5.4.  Model of co-ordinated airway and vascular growth regulated by SPRY2 
in the fetal lung.  A.  FGF10 binds to its receptor FGFR2b at the leading edge of the 
airway tip where it signals downstream activation of ERK1/2 and mTORC1, whilst 
also inducing phosphorylation of SPRY2 at its Y55 domain.  B. Phosphorylation of 
SPRY2 at Y55 exposes the C-terminal PXXPXR (SH3) motif where it recruits GRB2 
from the MAPK signalling cascade.  Subsequent silencing of GRB2 by cCBL results in 
the failure of ERK1/2 to become activated and airway growth is halted.  C.  Putative 
interaction between a GAP and the PXXPXR motif of SPRY2 leads to the inability of 
the GAP to activate mTORC1 in a PI3K-independent manner.  D.  In the event that 
mTORC1 is activated upon FGF10 stimulation, mTORC1 binds to HIF-1α and induces 
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its translocation to the nucleus.  E.  Upon nuclear translocation, HIF-1α promotes 
VEGF-A gene expression and subsequent vascular growth through interaction with 
its transcriptional co-activator, CBP/p300.  F.  SPRY2 acts to repress histone 
acetyltransferase activity through binding to ‘CpG island’ methylation sites on the 
VEGF-A promoter and subsequently silences transcriptional activation of the VEGF-A 
gene. 
 
The clinical significance of SPRY2. 
 
Lung cancer is the major cancer-related death worldwide and approximately 1.3 
million people die annually from this disease (Lockwood et al., 2010).  While SPRY2 is 
a known tumour suppressor for this cancer (Sutterlüty et al., 2007), it has also been 
extensively described to have a similar function in a number of other cancers, 
including that of the breast, liver and prostate (Gao et al., 2012; Lo et al., 2004; 
Wang et al., 2012b).  How SPRY2 is down-regulated in cancer is unclear; however, it 
has been reported that in Human Heptaocellular Cell Carcinoma (HCC) and prostate 
cancer, SPRY2 is silenced epigenetically through promoter hypermethylation, where 
in HCC it triggers an increase in the FGF-induced MAPK-signalling (Lee et al., 2010). A 
diagnostic feature of human cancer is the disruption of the RTK signal transduction 
pathway.  As a consequence, the majority of studies examining the role of SPRY2 as a 
tumour suppressor gene have focused on its ability to suppress RTK signalling.  Shaw 
et al., (2007) reported on this by showing that mice bearing a V-Ki-ras2 Kirsten Rat 
Sarcoma Viral Oncogene Homolog (KRAS) mutation developed fewer tumours upon 
up-regulation of SPRY2.  A subsequent study by Sutterlüty et al., (2007), further 
confirmed the tumour suppressor function of SPRY2 upon RTK signalling by 
examining SPRY2 expression in both KRAS WT and mutant NSCLC lines.  The results 
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in this thesis demonstrate that the loss of SPRY2 results in unsustainable FGF10-
induced MAPK activity thereby leading to possible unsustained development of the 
airway.  However, Sutterlüty et al., 2007 also established that SPRY2 down-
regulation in NSCLC could potentially interfere with another unidentified RAS-
independent pathway.   
 
Could this pathway be that of the vascular signalling pathway governed by SPRY2 
independently of PI3K/AKT?  The observations in this thesis showed that the loss of 
SPRY2 correlated with a marked increase in mTORC1 and VEGF-A activity in hypoxia.  
Under this presumption, the FGF10 proliferative signal is unsustainable through the 
loss of SPRY2 expression, which could lead to inflammation and hyper-vascularity of 
the developing lung.  On the other hand, the results in this thesis report the novel 
observation that a loss of SPRY2 in normoxia drastically elevates HIF-1α 
transcriptional activity, possibly caused by the inability of pVHL to interact with 
SPRY2.  The role of HIF-1α in normoxia is poorly characterised but it is thought to 
potentially play a role in tissue homeostasis (Stroka et al., 2001).  However, HIF can 
be activated in cancer which has been reported to be caused by inactivation of 
tumour suppressor genes (Talks et al., 2000) and overexpression of HIF-1α has been 
observed in many cancers (Ke & Costa, 2006).  Given that SPRY2 is a known tumour 
suppressor gene and how it has been manipulated in the HBE cell line, it is possible 
that silencing of the SPRY2 gene promotes unsustained HIF-1α transcriptional 
activity, which disrupts tissue homeostasis leading to increased potential for 
tumourigenesis.  The evidence from the results presented in this study and that of 
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the literature provide further indication that SPRY2 may be a novel therapeutic 
target for treating lung diseases such as asthma and cystic fibrosis. 
Experimental limitations of this study. 
 
To date, studies of SPRY2 function have been confined to in vitro cell models through 
the use of transient or stably transfected cell lines (Gao et al., 2012).  For the 
purposes of this study, there are a number of ethical issues that are raised regarding 
the use of a fetal in vivo model so the closest representation of such a model was 
represented ex vivo by the primary cultured FDLE isolated from E19 rat lungs and 
through the use of the HBE immortalised cell line.  The effects of FGF10 and SPRY2 
on HAT/HDAC activity in FDLE were further examined by carrying out HAT/HDAC 
assays.  However, the results were not informative but with improvements made to 
this procedure, then it is possible that an effect could be determined.  It should be 
noted that some of the variation observed in the data could be attributed to the 
varying growth rates of each cell line, which made it difficult to establish similar cell 
confluence.  It should also be mentioned that in instances where the data did not 
infer statistical significance, the ideas which follow on from said data were driven by 
the trends observed. 
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Main Conclusions 
 
The original aim of this thesis was to establish a potential role for SPRY2 in co-
ordinating airway and vascular growth of the fetal lung.  The main findings from this 
project provide evidence that SPRY2 does indeed play a role in both facets of growth 
while shedding some light on several possible mechanisms through which this co-
ordinated development is achieved.  FGF10 stimulation induces Y55 phosphorylation 
and C-terminal activity of the SH3 domain of SPRY2, which is required to suppress 
both airway (which is known) and vascular signalling cues via the MAPK and mTORC1 
respectively.  SPRY2 is present in the nucleus of both fetal and adult lung epithelium 
where it acts to repress HAT activity, regulate cell-cycle progression (specifically 
CCND1 expression) and bind to methylation sites of the VEGF-A promoter thus 
regulating the expression of vascular genes. This thesis also provides a novel function 
for the CRD of SPRY2, whereby this region plays a role in regulating HIF-driven VEGF-
A transcription. Furthermore, SPRY2 appears to facilitate HIF-1α degradation at 
normoxia thereby further implicating its role as a tumour suppressor.  Therefore, the 
results presented in this thesis appear to be in agreement with the original 
hypothesis, which stated that: ‘SPRY2 acts as the “missing link” that governs co-
ordinated development of the airway and vascular trees in the fetal lung’ where it 
acts as a link between its role as a negative feedback regulator of FGF10-induced 
airway outgrowth and its role in regulating FGF10-induced transcriptional activation 
of the VEGF-A gene. 
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Future direction 
 
While the work in this thesis presents several novel functions for SPRY2 in facilitating 
co-ordinated lung development, a number of ambiguities persist.  One such 
ambiguity surrounding SPRY2 function is its translocation to the cell membrane, 
possibly upon cys-palmitoylation, which is influenced by growth factor stimulation or 
through modifications made to its CRD.  A recent unpublished observation from our 
lab has determined that SPRY2 is indeed palmitoylated in FDLE and the ability of the 
full-length form of SPRY2 to become palmitoylated is governed by FGF10 
stimulation.  At the time of writing, an experiment had been conducted to assess if 
mutations made at C218 and C221 of SPRY2 led to the failure of SPRY2 to 
palmitoylated to the cell membrane.  Preliminary results have revealed that C221 
mutation abolishes SPRY2 palmitoylation to the cell membrane.  These experiments 
may answer the ‘unanswered questions’ queried by Guy et al., (2009) surrounding 
the true function of the CRD of SPRY2. 
 
It is also important to consider that this regulatory function of SPRY2 is not just 
confined to the developing lung and that its expression extends to several organ 
systems.  This is highlighted by recent unpublished work from our lab, which has 
established populations of SPRY2 and SPRY4 in the nuclei of SHS5Y neurons, a cell 
line extensively used in research of Alzheimer’s disease.  Not only were SPRY2/4 
strongly nuclear in these cells, further IHC analysis determined that they are both 
involved in cell division, thus providing further evidence that SPRY may epigenetically 
regulate the development of these cells.  Clearly, more work is required here but it is 
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possible that the role of SPRY2 in the developing lung established in this thesis may 
translate to other organ morphogenetic/developmental systems.  As stated earlier in 
this discussion, the loss of SPRY2 correlates with the rise in cancer in a number of 
organs and tissues which highlights the need for further work to establish SPRY2 as a 
potential therapeutic agent.   
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